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Abstract
Miller, Kelly Lynn Robbins. Ph.D., Biomedical Sciences Ph.D. Program, Wright State
University, 2010. Induction of p53 Dependent Cellular Senescence through HdmX
Inhibition or YPEL3 Expression.

Mutations in p53 that compromise its function have been reported in
approximately half of all human cancers (Vousden et al., 2002). The other half of human
tumors that retain wild-type p53 have a dysfunctional p53 pathway through other
mechanisms (Wade et al., 2009). Activation of p53 leads to cell cycle arrest, DNA
repair, apoptosis and senescence, however, the pathway leading to cellular senescence is
the focus of this study. Cellular senescence is a process leading to irreversible arrest of
cell division. Under normal physiologic conditions, the activity of p53 is kept in check
by its negative regulators, Mdm2 and MdmX. While MdmX overexpression has been
linked to human tumor formation, the mechanism has yet to be elucidated. The first part
of this thesis describes the ability of HdmX to block oncogenic Ras mediated senescence
in human diploid fibroblasts (HDFs) through interactions with Hdm2 and p53,
elucidating a potential mechanism for HdmX’s contribution to tumor formation.
Furthermore, senescence induction was demonstrated when HdmX was reduced in
prostate adenocarcinoma cells (mutant Ras, wild-type p53, high HdmX), suggesting that
targeting HdmX in tumor cells with this genotype may be a useful anti-cancer therapeutic
approach.
In part two of this thesis, a novel-p53 target, YPEL3, was described as a
senescence inducer in non-transformed and human tumor cell lines. YPEL3, acting
downstream of p53, was shown to be required for oncogenic Ras mediated senescence
iv

but functions as a senescence inducer independent of p16 or p21 expression in HDFs,
suggesting its critical nature to senescence signaling. In accordance with its potential
activity as a tumor suppressor protein, YPEL3 expression was found to be differentially
regulated in breast tumor versus normal tissue. In the third part of this thesis, I
discovered that YPEL3 is down-regulated by ERα signaling in a p53 independent
manner. Estrogen depletion of MCF7 cells led to activation of YPEL3 and induction of
cellular senescence of this breast carcinoma cell line, suggesting that YPEL3 may be a
valid therapeutic target for treating ER+ breast tumors. This study describes novel
mechanisms that are involved in the activation of p53 and subsequent downstream targets
leading to cellular senescence.
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I. Introduction and Purpose
Cancer is the second leading cause of all deaths in the United States, accounting
for 23% of those occurring in 2006 (Jemal et al., 2009). Although second to heart
disease in overall deaths per year, cancer accounts for the highest number of deaths in
persons younger than 85 years of age. A total of 1,479,350 new cancer cases were
projected to occur in the United States in 2009 (Jemal et al., 2009). The good news is
that through advances in prevention, early detection and treatment, the overall cancer
death rate is on the decline. However, there are many types of cancer, including but not
limited to ovarian, lung or pancreatic cancers, that still have no tools for early detection
and few, if any, treatment options which leaves patients and their families with little
hope. In order to keep the death rate on the decline and obtain treatments options for all
forms of cancer, researchers must continue to provide information that aids in effective
early detection and treatment development.
Common to all tumor formation is inactivation of the p53 pathway. Due in large
part to this finding, the tumor suppressor protein, p53, has become one of the most widely
studied genes in cancer research today. Determining the precise mechanisms involved in
p53 pathway functioning may elucidate promising early detection and anti-cancer
treatment targets. The goal of this study is to highlight novel discoveries in p53 pathway
regulation and function with the intent of providing insight into potential anti-cancer drug
1

targets. To this end, it is first necessary to review pertinent findings related to p53
structure and function.
p53 Structure and Function
Encoded by the TP53 gene residing on the short arm of chromosome 17, the
tumor suppressor protein p53 was initially discovered by two labs in 1979, Lane and
Crawford along with Linzer and Levine, whose results are published in Nature and Cell,
respectively (Lane et al., 1979; Linzer et al., 1979). Discovered for its ability to bind
Large T antigen from Simian Virus 40, p53 was initially described as an oncogene
(Crawford et al., 1981). It was not until years later that p53 was correctly defined as a
tumor suppressor protein (Baker et al., 1989; Finlay et al., 1989). p53 has since been
famously coined the “guardian of the genome” for its role in preventing genome mutation
and conserving stability.
This 393 amino acid protein can be divided into five functional domains: a
transactivation domain, proline rich domain, DNA binding domain, oligomerization
domain and a regulatory domain (reviewed by Balint et al., 2001; Figure 1). The
transactivation domain (1-63) binds regulatory proteins like Mdm2, which is a negative
regulator of p53 (Momand et al., 2000) and p300/CBP, which functions as a histone
acetyltransferase acting to increase the expression of p53 target genes (Grossman, 2001).
The proline rich domain (64-92) is considered a regulatory region and has been indicated
to have a role in signal transduction through its SH3 domain binding activity (Walker et
al., 1996).

2

Figure 1: Domain Structure of p53 Protein. Schematic representation of the
five functional domains of p53. The transactivation domain contains amino acids
1-63, proline rich domain 64-92, sequence specific DNA binding domain 94-292,
oligomerization domain 326-355 and regulatory domain 363-393. NLS = nuclear
localization sequence, NES = nuclear export sequence (Balint et al., 2001).
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The majority of tumor-derived p53 mutations occur in the sequence specific DNA
binding domain or central region of the protein (94-292), which is the region that directly
contacts DNA. The oligomerization domain (326-355) is responsible for the
tetramerization of p53, which is the active form of this transcription factor. Assuming
that a mutation that occurs in the central domain of p53 renders the protein nonfunctional but it retains its ability to oligomerize, then the presence of a single mutant
within the p53 tetramer might disturb the overall function of p53. Essentially, mutant
forms of p53 can function as dominant negatives or gain-of-function proteins in this
manner. The remaining carboxy-terminus of the protein (363-393) contains a negative
auto-regulatory domain with acetylation and phosphorylation sites that help to regulate
the DNA binding activity of p53 (Prives et al., 2001).
p53 transactivation is increased following genotoxic (DNA-damaging) stress and
activates target genes involved in cell cycle arrest, apoptosis, DNA repair and senescence
(Ashcroft et al., 1999). Additionally, knock-out studies in mice demonstrated that loss of
p53 led to a shortened life span (6 months) where most mice died from lymphomas and
sarcomas (Donehower et al., 1992). Mutations in p53 that compromise its function have
also been reported in approximately half of all human cancers (Vousden et al., 2002).
The other half of human tumors that retain wild-type p53 have a dysfunctional p53
pathway through other mechanisms (Wade et al., 2009). Taken together these results
support that p53 functions as a tumor suppressor protein limiting or blocking the
development of cancer. It is the necessity for a tumor to inactivate the p53 pathway that
makes understanding how p53 is activated and what genes it controls essential to
advancement of cancer treatment.
4

Cellular Senescence
Activation of p53 leads to cell cycle arrest, DNA repair, apoptosis and senescence
as mentioned previously. While all end-points are important, the pathway leading to
cellular senescence is the primary focus of this study. Cellular senescence is a process
leading to irreversible arrest of cell division. Cells that undergo senescence cannot divide
upon mitogen stimulation, but they remain metabolically and synthetically active. There
are two types of senescence, accelerated and replicative. Replicative senescence was first
described in 1965 by L. Hayflick when he noticed that human diploid cells have a limited
in vitro lifetime (Hayflick, 1965). Replicative senescence has further been demonstrated
to be a function of telomere shortening with age and demonstrated in tissues and in vivo.
Accelerated senescence prevents the uncontrolled growth of cells that have undergone
some insult, like oncogenic Ras mutation (Ferbeyre et al., 2002). Both of these processes
require functional p53 and are considered protective mechanisms against tumor
formation.
Senescent cells undergo characteristic changes in morphology that are utilized to
measure senescence in the laboratory. They show an enlarged and flattened shape, have
increased beta-Galactosidase activity at pH 6, and develop a distinct chromatin structure
referred to as senescence associated heterochromatin foci (SAHF) (Figure 2 a and b)
(Dimri et al., 1995; Narita et al., 2003). In addition, senescent cells have also been
indicated to characteristically alter expression patterns of certain genes including, but not
limited to, p16, p21 and PAI-1. It appears that the expression of “senescence markers” is
cell type and senescence inducer specific making their utility as a measure of senescence
5

Figure 2: Senescent Phenotype. (a) and (b) proliferating (upper) and Ras infected
senescent (lower) WI-38 fibroblasts stained with SA-β-gal (a) or DAPI (b). Senescent
cells show increased SA-β-gal activity (blue, a) and chromatin condensation (b) (Narita
et al., 2003).
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limited. However, the aforementioned morphological changes specific to a senescent cell
give us the tools necessary to study the pathways leading to senescence.
There are two tumor suppressor protein networks, p53 and the Retinoblastoma
protein family (Rb/p107/p130), that control the central activating pathways leading to
senescence (Ben-Porath et al., 2005; Figure 3). Both p53 and the Rb family have been
shown to be activated in senescent cells with p53 being implicated in the induction and
the Rb family in the maintenance of senescence. p53 serves to activate its transcriptional
targets such as p21, while Rb is active during senescence in its hypophosphorylated form
and binds the E2F protein family members to repress their transcriptional targets. Many
targets of E2F proteins, upon transcription, play a role in cell-cycle progression. While
the Rb family is important to senescence, the focus of this proposal will be on the p53
pathway.
There are two major pathways that act upstream to induce p53 during the
induction of senescence. The DNA damage response mediated by ATM/ATR and
Chk1/Chk2 causes post-translational stabilization of p53 through its phosphorylation and
p19/p14/Arf (Alternative Reading Frame, p19Arf in mouse cells and p14Arf in human
cells) activates p53 by sequestration of Mdm2, a negative regulator of p53 (Ben-Porath et
al., 2005). The Arf protein, encoded at the INK4a locus with p16, is induced in situations
of stress like the presence of oncogenic Ras or myc. Once p53 is activated, there are
downstream targets that have been implicated in the senescence pathway, including p21,
which is a cyclin dependent kinase inhibitor that inhibits the activity of cyclin-CDK2 and
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Figure 3: p53 and Rb are the Main Activators of Senescence Schematic
representation of known key players of the senescence pathway (Ben-Porath et
al., 2005).
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CDK4 complexes to regulate cell cycle progression at G1. While activation of p21 is
required for senescence induction in most situations, other p53 targets that are critical to
the senescence pathway is an active area of research. It is clear, however, that the
induction of senescence happens through a dynamic mechanism where key regulators are
turned on and off in a specific manner.
The studies of senescence are further confounded by differences in the senescence
pathway that exist between human and mouse fibroblasts cell culture systems where most
of the senescence pathway discoveries have been made. While it appears that p53 and
the Rb family are the critical mediators of senescence induction and maintenance, other
regulators of the senescence pathway are not as clearly defined. For example, the
inactivation of p21 is sufficient to prevent senescence in human cells (Brown et al., 1997)
while p21-null MEFs undergo replicative and oncogenic Ras induced senescence
normally (Pantoja et al., 1999). This implies that there is a missing link between the p53
and the Rb family pathways or that other proteins can compensate for p21 in the mouse
system.
It is unclear in the literature whether there is a linear activation of p53 through
p21 to Rb or a parallel activation of p53 and Rb during cellular senescence. It seems that
both models may be correct and the function of p16INK4a, a direct input line to Rb, may
determine which model is carried out in various cell types. p16 is not normally expressed
in human adult tissue, but is induced during senescence in MEFs and HDFs. Its
inactivation blocks senescence in human but not mouse cells, suggesting that the
relevance of the p16 arm of the senescence pathway is enhanced in human cells (Brookes
9

et al., 2002; Duan et al., 2001). Interestingly, ARF, the other protein encoded at the
INK4a locus with p16 (Figure 3), is not up regulated to the same extent during
senescence in humans as in mouse cells and is required for senescence in mouse but not
human cells. In any case, it is clear that p53 and the Rb family function as a complex,
stress-signal integration and processing unit that detects various stress stimuli and
activates the appropriate proteins to carry out the necessary cellular response.
Interestingly, tumor cells have been indicated to undergo accelerated senescence
by genetic manipulation or treatment with chemotherapeutic drugs, radiation, or
differentiating agents (Roninson 2003). Clinical data also indicates that expression of
different biological classes of senescence-associated growth-regulatory genes, like p53,
in tumor cells has significant prognostic implications (Roninson 2003). Additionally, the
discovery that a brief reactivation of p53 in a mouse liver carcinoma model leads to
cellular senescence followed by tumor regression through clearance of these cells by the
innate immune system has provided a foundation for senescence as a favorable outcome
for anti-tumor drug discovery (Xue et al., 2007). Uncovering the specific genes and
regulatory mechanisms responsible for the induction and maintenance of tumor cell
senescence will aid in the design of new anti-cancer therapeutics.
Hdm2 and HdmX
Under normal physiologic conditions, when programs like senescence are not
initiated, the activity of p53 is kept in check by its negative regulators, Mdm2 (Hdm2)
and MdmX (Mdm4, HdmX). Mdm2 physically associates with p53 targeting it for
degradation and inhibits p53-mediated transcriptional activation (Marine et al., 2007).
10

Mdm2 over expression is a known mechanism for promoting tumor formation, especially
in human sarcomas (Oliner et al., 1992). MdmX inhibits only the transcriptional
activation of p53 and is over expressed in several human tumors, the majority of which
contain wild-type p53 (Table 1). For example, MdmX has been demonstrated to be over
expressed in approximately 19% of breast carcinomas and targeting MdmX using RNAi
technology in MCF7 breast carcinoma cells led to a G1/S cell cycle arrest accompanied
by an increase in p53 and p21 (Danovi et al., 2004; Heminger et al., 2009). These and
several other similar studies have suggested roles for MdmX in human tumor formation.
Mdm2 and MdmX are structurally related proteins that have similar p53 binding
domains at the N-terminus and a RING-finger domain at the C-terminus (Figure 4).
Contrary to Mdm2, MdmX is a more stable protein and is thought to be regulated
primarily by post-translational modifications, making protein-protein interaction and
subcellular localization studies important in determining roles for and regulation of
MdmX (Tanimura et al., 1999; Marine et al., 2007). MdmX not only interacts with p53,
but also heterodimerizes with Mdm2. Most transfection studies indicate that this
interaction regulates Mdm2 and MdmX protein stability (Marine et al., 2007). It is
known that Mdm2 and MdmX carry out non-redundant functions to keep p53 levels low
throughout development. There are two main models for why MdmX and Mdm2 cannot
compensate for each other in vivo, suggested by the fact that too little Mdm2 or MdmX
elicits lethality whereas an excess of either can be oncogenic. The first view is that
MdmX and Mdm2 contribute to the regulation of p53 independently (Danovi et al., 2004;
Laurie et al., 2006). The second is that Mdm2 and MdmX form a complex that is more

11

Table 1 : Tumors with Either Increased Mdmx Copy Number or Increased
Mdmx mRNA. Various human tumor tissue samples or cell lines were evaluated
for MdmX expression and this table was compiled in a review by Wade and Wahl,
(2009).

12

Figure 4: Comparison of Mdm2 and MdmX Structural Domains. Mdm2 and
MdmX contain p53-binding, acidic, zinc (Zn) and ring finger domains (Marine et al.,
2007). NLS = nuclear localization sequence, NES = nuclear export sequence,
hMDM2 = human version of Mdm2, hMDMX = human version of MdmX, NoLS =
nucleolar localization sequence, RING = ring finger domain.
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effective at inhibiting p53 transactivation or enhancing p53 turnover than either alone
(Wade et al., 2009). Evidence exists to support each view, so exactly how MdmX
functions to inhibit p53 and the regulation of this interaction remains to be determined.
While probing the direct contribution of MdmX to tumor formation, Danovi and
colleagues (2004) noticed that MdmX could cooperate with oncogenic Ras (H-RasV12,
constitutively activated) in the neoplastic transformation of MEFs (mouse embryonic
fibroblasts) and that MdmX/H-RasV12 infected MEFs were no longer contact inhibited
and formed tumors within three weeks when subcutaneously injected into nude mice
(Figure 5). Tumors were confirmed to retain p19Arf, p53, and MdmX. It is important to
note that infection of H-RasV12 alone into MEFs causes accelerated senescence, as
previously described.
Additionally, mitogenic signaling has been shown to induce MdmX expression at
the transcript level (Gilkes et al., 2008). This regulation of MdmX expression may
prevent unwanted p53 activation during normal cellular proliferation; however, when
inappropriately activated, this pathway may block the tumor suppressive functions of p53
during abnormal cellular proliferation leading to initial tumor formation. Together with
the over expression of MdmX in MEFs blocking oncogene induced senescence, these
activities of MdmX represent potential mechanisms for how HdmX over expression
contributes to human tumor formation.
The pathways leading to senescence in murine and human cells have similarities
and differences, as described previously. While it has been demonstrated that MdmX can
block oncogene induced senescence in mouse cells, the question remains as to whether
14

Figure 5: MdmX Bypasses HRasV12 Induced Senescence and Cooperates with
HRasV12 in Neoplastic Transformation. Animals were injected with MEFs
expressing RasV12 (not pictured, no tumor), MdmX, MdmX/RasV12 or E1A/RasV12 at
6-8 weeks of age and were inspected for appearance of tumors 3 weeks later (Danovi
et al., 2004; Figure 3). Numbers represent # of mice positive for tumor
formation/total number of mice examined. E1A+Ras infection was used as a positive
control and MdmX infection alone as a negative control.
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HdmX retains this ability in human cells and the mechanism through which this outcome
is achieved.
Mdm2 (Hdm2) has been implicated in the senescence pathway through its wellestablished interaction with Arf (Pomerantz et al., 1998). In response to a variety of
oncogenic stimuli, Arf expression causes a rapid increase in p53 levels through its ability
to bind Mdm2 and inhibits Mdm2’s action on p53. Specifically, Arf functions by
sequestering Mdm2 in the nucleolus, away from p53. In many human tumors,
inactivation of the INK4a locus can be demonstrated representing another mechanism for
deregulation of the p53 pathway.
YPEL3
Once p53 has been activated, it acts as a transcription factor to regulate
genes that are involved in mechanisms like cell cycle arrest and senescence. In order to
study novel p53 regulated genes, a microarray experiment was completed where the
negative regulators of p53 (Hdm2 and HdmX) were silenced in MCF7 breast carcinoma
cells using siRNA technology (Heminger et al., 2009). MCF7 cells contain wild-type
p53, therefore, knocking down Hdm2 and HdmX allowed for the non-genotoxic stress
induction of p53. This led to a G1 phase cell cycle arrest along with sensitization of the
arrested MCF7 cells to DNA damage (Heminger et al., 2009). From analysis of the
microarray data, a novel p53 target was discovered named YPEL3 (yippee-like protein
3). Further validation studies, including chromatin immunoprecipitation (ChIP),
confirmed that YPEL3 is a direct p53 target gene (Kelley et al., 2010).
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The Yippee gene was first identified in Drosophila through a yeast interaction
trap screen for proteins that interact with Hemolin, a member of the immunoglobulin
superfamily (Roxstrom-Lindquist et al., 2001). Hemolin is known to be up regulated
during development and also binds bacteria and lipopolysaccharide during bacterial
infection. The biological role for this interaction has not been elucidated. Later, five
human Yippee-like genes, including YPEL3, were described in human and mouse tissues
(Hosono et al., 2004; Figure 6) YPEL3 was found to be ubiquitously expressed in human
fetal tissues (Figure 6) and to have high sequence conservation between a wide range of
species (Roxstrom-Lindquist et al., 2001). Interestingly, human and mouse YPEL3 have
100% sequence identity (Hosono et al., 2004).
Although no further experiments have been reported that describe the interaction
of Drosophila YPEL3 with Hemolin, S.J Baker (2003) described the biology of a small
unstable apoptotic protein (SUAP) which was subsequently determined to be YPEL3.
Using a murine myeloid precursor cell line, apoptosis was induced by IL-3 deprivation
and granulocyte colony stimulating factor treatment followed by RNA analysis. YPEL3
was induced in the apoptotic myeloid precursor cells compared to normal, growing cells
with IL-3 present (Baker, 2003). Additionally, YPEL3 was also found to be rapidly
degraded by the proteasome which led to the descriptive name of small unstable
apoptotic protein. It is undetermined whether YPEL3 acts as a growth suppressor in
human cells, and if so, through what mechanism.
As a direct p53 target and potential growth suppressor, our lab investigated
whether YPEL3 expression was decreased in various human tumor tissues versus normal
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Figure 6: Expression Profiles of Human and Mouse YPEL Genes in Various
Tissues. RT-PCR was carried out using cDNA’s derived from various organs and
tissues from mouse (left panel) and human (right panel). Expression profiles for
mouse and human are similar. The arrow head of YPEL3 indicates an extra band seen
in pancreas, placenta and testis considered to be a product of alternative splicing
(Hosono et al., 2004; Figure 3).

18

control. In a screen of eight different tumor types, it was noted that YPEL3 expression
correlated with estrogen receptor status in breast tumor samples (personal
communication, Rebecca Tuttle MD). YPEL3 was also uncovered during a microarray
study in a list of genes that do not contain an estrogen response element that are down
regulated by estrogen in an ER+ breast tumor cell line (Cicatiello et al., 2010). These
findings led to the investigation of YPEL3 regulation by the estrogen receptor.
Estrogen Receptor
As mentioned previously, inactivation of the p53 pathway is one of the most
frequent events in cancer formation. Breast cancers are unique in that mutations in p53
itself occur in only about 20% of breast tumors (Liu et al., 2008). For most breast
cancers, wild-type p53 is inactivated by other mechanisms, which are largely unknown.
It has been reported recently that ERα directly binds to p53 and represses its function
providing a mechanism for p53 deregulation in ER+ breast cancers (Liu et al., 2006).
Additionally, ER- breast tumors have a higher incidence of p53 mutations compared to
ER+ tumors (Troester et al., 2006), making the reactivation of wild-type p53 an attractive
anti-cancer therapeutic goal for ER+ tumors.
Estrogens function through ER’s to regulate many physiological processes in a
p53-independent manner including but not limited to normal cell growth, development
and tissue specific gene regulation in the reproductive organs, bones, brain and other
tissues (Matthews et al., 2003). The biological activities of estrogen are mediated by two
estrogen receptors, namely ERα and ERβ, as reviewed by Matthews et al. (2003). As
members of the nuclear receptor superfamily, ERα and ERβ serve as ligand-regulated
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transcription factors. Ligand binding to either estrogen receptor causes conformational
changes in the receptor leading to dimerization, protein-DNA interaction and recruitment
of other co-regulators and transcription factors. It is also known that ER’s regulate gene
expression through their own response element and interactions with other transcription
factors, as mentioned previously with p53 (Matthews et al., 2003). Some mechanisms of
estrogen signaling are independent of DNA binding, referred to as non-genomic
regulation. While the focus for this study is on ERα, it should be mentioned that ERβ is
known to antagonize ERα mediated transcriptional activity and is gaining attention as an
important ER family member.
Recent advances in breast cancer treatment have been focused on hormone
receptor status determination of the tumor. The current standard of treatment for breast
cancer patients includes assessment of human epidermal growth factor receptor-2 (Her2), estrogen receptor (ER), specifically the α subtype, and progesterone receptor (PR)
status of the tumor by immunohistochemistry. The hormone receptor status has
implications for which therapeutic options will be utilized. For example, Tamoxifen is
used in women to treat ER+ breast tumors for its specific ability to inhibit the binding of
estrogen to the estrogen receptor (reviewed by Osborne, 1998). This drug is not useful
for the treatment of ER- tumors.
Some drugs in current use have rather large side effect profiles making their use
difficult at times. For example, the adverse events reported for Tamoxifen include
menopausal symptoms (hot flashes, vaginal discharge), ocular toxicity, thromboembolic
events and most seriously an increase in endometrial cancer at a relative risk of 2.2 as
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compared with population-based rates (Osborne, 1998). Although these adverse effects
were only reported in a small percentage of those treated with Tamoxifen, they are still a
risk that some patients will not take. Additionally, almost half of the women with ER+
breast tumors treated with Tamoxifen demonstrate resistance (Ring et al., 2004). If new
anti-cancer drugs are developed that have more specific, down-stream targets then the
side effect profiles will be reduced, which is an ongoing research goal. For example,
targeting the downstream targets of the ER that are critical for growth suppression in
breast tumors would be more specific and potentially reduce the adverse effects noticed
when all ER signaling is blocked.
Purpose for Study
The goal of this study is to uncover precise, novel mechanisms that are involved
in the activation of the tumor suppressor protein p53 and subsequent downstream targets
leading to cellular senescence. While it has been demonstrated that p53 activation is
critical to senescence induction, the downstream p53 targets that are essential for this
process have not been fully elucidated. Therefore, this dissertation is designed to
investigate p53 activation and critical downstream targets that lead to senescence
induction in human cells. First, the activation of p53 leading to senescence will be
detailed by targeting a known p53 negative regulator, HdmX. Second, the novel p53
target YPEL3 will be described for its role as an inducer of growth suppression through
the induction of cellular senescence and I will begin to describe YPEL3’s location within
the current senescence pathway model. Third, the regulation of YPEL3 by the estrogen
receptor will be described for its impact on senescence in a breast carcinoma cell line.
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Together the results provided by these studies are intended to aid in the design of
effective anti-cancer therapeutics with the goal of tumor cell senescence leading to tumor
regression.
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II. Materials and Methods
Cell lines, Antibodies and Reagents
Human tumor cell lines, MCF7 (breast carcinoma), U2OS (osteosarcoma), H1299
(non-small cell lung carcinoma), LNCaP (prostate adenocarcinoma) were grown in
Dulbecco’s Modified Eagle’s Medium (DMEM; Cellgro) supplemented with 10% fetal
bovine serum (FBS) or newborn calf serum (NCS) and 10 µg/mL gentamycin unless
otherwise specified. The human diploid fibroblast cell line IMR90 (ATCC) and mouse
embryonic fibroblasts (MEF) were also grown in DMEM supplemented with 10% FBS
and 10 µg/mL gentamycin unless otherwise specified.
HdmX (Bethyl Laboratories, Inc.), p21 (C-19; Santa Cruz Biotechnology, Inc.),
p16 (C20; Delta Biolabs), Hdm2 (H221; Santa Cruz Biotechnology, Inc.), p53 (FL393;
Santa Cruz Biotechnology, Inc.), Estrogen Receptor (Ab-16; Thermo Scientific) and
YPEL3 (Proteintech) polyclonal antibodies were used as indicated. Hdm2 (SMP14;),
p53 (Ab-4, Ab-6; Calbiochem), V5 (Invitrogen), GFP (Invitrogen), Estrogen Receptor
(Ab-10; NeoMarkers) and β-actin (Sigma) monoclonal antibodies were used as indicated.
Horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit secondary antibodies
(Promega) were utilized along with Super Signal substrate (Pierce) for chemiluminescence detection of proteins.
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β-estradiol and Tamoxifen was purchased from MP Biomedicals, LLC. βestradiol was dissolved in ethanol and added to serum free DMEM for storage at -20°C.
Tamoxifen was dissolved in ethanol and stored at -20°C.
Lentivirus Generation, Titering and Infection
The ViraPowerTM Lentiviral Expression System available from Invitrogen was
utilized to generate replication incompetent, HIV-1 based lentivirus used to deliver and
express genes of interest in either dividing or non-dividing mammalian cells. Lentivirus
was generated following instructions supplied with the kit with only minor modifications.
Briefly, approximately 8 million 293FT cells were reverse-transfected using
Lipofectamine 2000 (Invitrogen) overnight with ViraPowerTM packaging mix along with
the gene of interest cloned into either the pLenti4, pLenti6 or pLKO.1 plasmid. All
pLenti plasmids used are listed in Table 2. This transfection mixture was removed the
following morning and 5.5 mL of complete media (DMEM containing 10% NCS and 10
µg/mL gentamycin) added. Lentivirus containing supernatant was harvested
approximately 48 hours post-transfection. Remaining cells and debris were removed
from the lentiviral containing supernatant by centrifugation at 1500 rpm for 3-5 minutes.
Lentiviral supernatant was stored in 1 mL aliquots at -80°C until further use.
Concentration of infectious lentiviral particles in the supernatant was determined
by transducing H1299 cells with 10 fold dilutions of lentivirus, selecting for stably
transduced cells using the appropriate selecting agent (pLenti4-Zeocin, pLenti6Blasticidin, pLKO.1-Puromycin) for approximately 7 days and then staining the cells
with 1% crystal violet in 70% methanol. The number of antibiotic resistant colonies was
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Lentiviral Plasmid
pLenti6-GFP
pLenti6-Hdm2
pLenti6-HdmX
pLenti6-HdmXC437G
pLenti6-HdmXG57A
pLenti6-H-RasG12V
pLenti6-RescueHdmX
pLenti4-shHdmX
pLenti4-shLacZ
pLenti4-YPEL3
pLKO.1-shcon
pLKO.1-shERα
pLKO.1-shp16
pLKO.1-shp21
pLKO.1-shp53
pLKO.1-shYPEL3(A)

Antibiotic
Resistance
Blasticidin
Blasticidin
Blasticidin
Blasticidin
Blasticidin
Blasticidin
Blasticidin
Zeocin
Zeocin
Zeocin
Puromycin
Puromycin
Puromycin
Puromycin
Puromycin
Puromycin

pLKO.1-shYPEL3(B)

Puromycin

Company or Person Responsible
for Cloning
Steven Berberich
Steven Berberich
Steven Berberich
Kelly Miller
Kelly Miller
Steven Berberich
Nick Maiorano
Kate Heminger, BMS Thesis
Kate Heminger, BMS Thesis
Kevin Kelley, BMS Thesis
Addgene; Plasmid 1864
Sigma; NM_000125
Sigma; NM_058197
Sigma; NM_000389
Addgene; Plasmid 19119
Open Biosystems; RMM398199225223
Sigma; NM_031477

Table 2: Lentiviral Plasmid Name, Antibiotic Resistance and Company or
Person Responsible for Cloning.
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counted for each dilution and a viral titer calculated indicating the number of infectious
viral particles per mL (IVP/mL). Titers generally ranged from 105-106 IVP/mL. For
lentivirus that we were unable to use in this colony formation type assay for biological
reasons (YPEL3 for example) the QuickTiterTM Lentivirus Quantitation Kit (Cell
Biolabs, Inc.) was utilized to determine lentivirus physical titer. The physical titer was
correlated to a functional titer number through a conversion factor determined by
comparison of GFP physical titer and infectious titer numbers.
To infect tumor and non-transformed adherent cells, lentiviral supernatant was
thawed and diluted in complete media plus 6 µg/mL Polybrene. Lentivirus was used at a
multiplicity of infection (MOI) of 5 or a volume equal to or less than half of the total
volume of the infection cocktail. Cells were incubated with infection cocktail overnight
(at least 18 hours) and then removed and replaced with complete media. The appropriate
antibiotic selection was added 24 hours later and continued for 6-14 days until the control
plate of uninfected cells were dead. Kill curves were previously determined by Kate
Heminger (BMS Thesis; Table 3) to determine the lowest effective dose for selection of
some of the tumor cell lines used. Additional kill curves were completed for other cell
lines not previously studied (Table 3).
Quantitative RT-PCR
Cells were rinsed once in Dulbecco’s Phosphate Buffered Saline (DPBS) and
lysed on the culture dish with TRK Lysis Buffer supplemented with β-mercaptoethanol
(20 µL of β-mercaptoethanol per 1 mL of TRK Lysis Buffer) and total RNA was isolated
per the manufacturer’s instructions (e.Z.N.A. Total RNA kit; Omega Bio-Tek). The
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Cell Line
MCF7*
U2OS*
IMR90
LNCaP

Zeocin (µg/mL)
750*
500*
100
250

Blasticidin (µg/mL)
6*
6*
5
5

Puromycin (µg/mL)
1
1
0.5-1
n/a

Table 3: Antibiotic Concentrations Used for Selection. *Generated by Kate
Heminger, BMS Thesis.
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RNA was quantified using the NanoDrop DN-1000 spectrophotometer. The purity of the
RNA was estimated by the ratio of the absorbance at 260 nm and 280 nm (A260/A280),
with pure RNA having a ratio of 1.8-2.1. One µg of each RNA sample was reverse
transcribed with random hexamers to create cDNA using the TaqMan Reverse
Transcription Kit (Applied Biosystems) per the manufacturer’s instructions. The reverse
transcription (RT) reaction was performed in an Applied Biosystems Gene Amp PCR
System 2700 programmed to sequentially cycle as follows: initial 10 minute incubation at
25°C, 30 minute RT step at 48°C, 5 minute inactivation step at 95°C, and an infinite hold
at 4°C. After RT was complete the cDNA was diluted in 120 µL of sterile DNAse-free
water.
Quantitative real-time PCR was performed in a 96-well microtiter plate format on
an ABI 7900HT sequence detection system. A 20 µL reaction was prepared by mixing 9
µL of cDNA/water mix, 10 µL of 2X TaqMan Universal PCR master mix and 1 µL of
Assay-on-Demand Gene Expression product (Applied Biosystems; contains primers and
a fluorescent Taqman probe) designed for the gene of interest, to each well on the 96 well
plate. The PCR conditions include a 2 minute hold at 50°C, a 10 minute hold at 95°C
followed by 40 cycles of a 15 second 95°C denaturing step and a 1 minute 60°C anneal
and elongation step. Each cDNA sample was separately analyzed in triplicate for target
gene expression normalized to the internal control of GAPDH. The fold change (RQ)
relative to the control sample was calculated which is normalized to GAPDH control
RNA levels using SDS 2.0 software (ABI). The mean RQ values are plotted and the
error bars represent 95% confidence intervals.
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Western Blot Analysis
Cells were harvested by removing media, washing once with cold DPBS and
scraping the cells into 1 mL of DPBS. This cell mixture was transferred to a 1.7 mL
Eppendorf tube, spun in a refrigerated microfuge at 10,000 rpm (8,161 x g) for 2 minutes
to pellet cells. Excess DPBS was removed without disturbing the pellet then tubes were
stored at -80°C until further use. Total cell lysates were prepared by thawing the cell
pellet on ice in 25-100 µL RIPA buffer (25 mM Tris-HCl pH7.6, 150 mM NaCl, 0.1%
SDS, 1% NP-40, 1% sodium deoxycholate) supplemented with protease inhibitor cocktail
(PIC) and pipetting up and down to lyse the cells. The cell suspension was incubated on
ice for 15 minutes followed by centrifugation in a refrigerated microfuge at 14,000 rpm
(15,996 x g) for 10 minutes and then the soluble protein fraction was transferred to a new
1.7 mL Eppendorf tube. Protein concentration was determined using the Bradford
method by mixing 1 µL of the whole cell extract with 799 µL of sterile distilled water
(SDW) and 200 µL of Bradford reagent (Bio-Rad Inc.). A standard curve was generated
using bovine serum albumin (BSA) protein ranging from 2-14 µg in 800 µL SDW and
200 µL Bradford reagent. Mixtures were transferred to a cuvette and the absorbance at
595 nm measured on a Spectronic Genesys 5 spectrophotometer. The standard curve
generated was used to determine the protein concentration of each sample from its
absorbance value. Then, 100 µg of protein in 1X SDS loading dye (diluted from 6X SDS
loading dye; 1X = 60 mM Tris, pH7.6, 2% SDS, 10% glycerol, 5% β-mercaptoethanol
and 1% bromophenol blue) was boiled at 100°C for 5 minutes prior to loading on a 12%
sodium dodecyl sulfate polyacrylamide gel using a Mini-Protean II Bio-Rad
Electrophoresis System. The gel was run at a constant 100 volts for approximately 1
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hour in 1X SDS running buffer (25 mM Tris pH 8.3, 250 mM glycine, 0.1% SDS). The
proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore)
(pre-soaked in 100% methanol for 10 seconds followed by SDW for 2 minutes) in a
transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3) using a Bio-Rad
transfer system for 40 minutes at a constant 50 mAmps. The membrane was then
incubated in 20 mL blocking buffer (1X Tris Buffered Saline (TBS), 5% non-fat dry milk
(NFDM), 0.1% Tween-20) on a shaker at room temperature for one hour. The blot was
then incubated in the appropriate primary antibody at 1:500-1:5,000 dilution in 1:10
blocking buffer on a shaker overnight at 4°C. The next morning the blot was washed
three times for 10 minutes each in 1:10 blocking buffer at room temperature on a shaker,
then the blot was shaken in the appropriate secondary antibody (goat anti-mouse or goat
anti-rabbit, both from Promega) at 1:5,000 dilution in 1:10 blocking buffer for 45 minutes
at room temperature. The blot was again washed three times for 10 minutes each in 1:10
blocking buffer and then exposed to Thermo Scientific SuperSignal West Pico or Femto
Detect chemiluminescent reagent (Pierce) for 3-4 minutes and protein visualized on a
FUJI FILM LAS 4000 image reader. If necessary, the antibodies were removed from the
membrane by shaking the blot in Western strip buffer (25 mM glycine, 1% SDS, pH 2.0)
for 20 minutes at room temperature. The membrane was then blocked and
immunoblotted using another antibody following the same procedure outlined above.
Colony Formation Assay
MCF7 and U2OS cells containing Tetracycline Repressor (100,000 cells/well)
were transduced with Lenti-YPEL3 or left untreated followed by incubation in complete
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medium for 24 hours. Following transductions, cells were selected with 750 μg/mL and
500 μg/mL Zeocin, respectively. Tetracycline was used at a concentration of 1 μg/mL
for induction of YPEL3-V5. After 15 days, the cells were stained with 1% crystal violet
in 70% methanol for five minutes. Plates were washed with DPBS for five minutes,
colonies counted and then photographed. The total number of colonies remaining in each
well was scored. The experiment was completed in duplicate for U2OS cells and
triplicate for MCF7 cells. Average number of colonies remaining with non-Tetracycline
treated wells set to 100% was reported +/- standard error of the mean.
Cell Proliferation Assay
At day zero, 50,000 cells (MCF7, MCF7shLacZ, MCF7shYPEL3(A),
MCF7shYPEL3(B), U2OS, U2OSshLacZ, U2OSshYPEL3(A) or U2OSshYPEL3(B))
were plated per well in a 6 well dish. Cells were re-fed each day with complete media.
On days two, four and six, 3 wells of a 6 well dish were trypsinized for 5 minutes using 1
mL of Trypsin-EDTA 1X (Cellgro). Trypsin was neutralized using 2 mL of complete
media and cell suspension was centrifuged at approximately 1700 rpm (250 x g) for 3
minutes to pellet the cells. Excess Trypsin/complete media was removed without
disturbing the pellet and cells were resuspended in 1 mL of complete media. This 1 mL
cell suspension was analyzed using a Beckman Coulter Vi-CellTM cell viability analyzer.
The total cell count and percent viability of each sample was provided by the Vi-Cell.
These numbers were used to graph the average viable cell number per cell type on days 2,
4 and 6.
Nuclear Cytoplasmic Protein Extraction
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IMR90 cells were transduced and selected as indicated. After approximately 8
days the cells were rinsed with 2 mL DPBS, scraped in 1 mL DPBS, transferred to a 1.7
mL Eppendorf tube and pelleted in a refrigerated microfuge at 10,000 rpm (8,161 x g) for
2 minutes. Using reagents supplied in the Nuclear/Cytoplasmic Fractionation Kit
(Pierce), the pellet was resuspended in 200 µL of cold CER I reagent by vigorously
vortexing. The cells were then placed on ice for 10 minutes. 15 µL of CER II reagent
was added to each sample and the cytoplasmic extract fraction was prepared. The
remaining pellet was resuspended in 90 µL of cold NER reagent and the nuclear fraction
was isolated per the instructions supplied with the kit. Protein concentration was
determined by Bradford method and SDS polyacrylamide gel and Western blot were
completed as previously described.
TNT Reaction
Bluescript plasmids containing HdmX, HdmXG57A, HdmXC437G, Hdm2 or p53
were used to generate protein using a TNT Coupled Reticulocyte Lysate System from
Promega. Briefly, biotinlyated lysine containing protein was generated mixing TNT
Rabbit Reticulocyte Lysate, TNT Reaction Buffer, TNT RNA Polymerase (T7), Amino
Acid mixtures (minus Leucine and minus Methionine), RNasin Ribonuclease Inhibitor,
DNA template, TranscendTM tRNA and nuclease free water. These reactions were
incubated at 30°C for 90 minutes. Resulting protein was utilized in a coimmunoprecipitation assay as described.
Site-Directed Mutagenesis
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The QuikChange XL Site Directed Mutagenesis Kit (Stratagene) was used to
generate pLentiHdmXG57A and pLentiHdmXC437G point mutations using the wildtype pLentiHdmX plasmid. Primers used with this kit were designed using Stratagene’s
Primer Design program available through their website. The sequences for the
HdmXG57A primers generated are (sense) 5’-gaggtcatgcactatttagctcagtacataatggtgaag-3’
and (antisense) 5’-cttcaccattatgtactgagctaaatagtgcatgacctc-3’. The sequences for the
HdmXC437G primers are (sense) 5’-ccagaatctcttgaagccaggtagcttatgtgagaaaag-3’ and
(antisense) 5’-cttttctcacataagctacctggcttcaagagattctgg-3’. To confirm mutagenesis
plasmids were sequenced by Retrogen.
Co-immunoprecipitation
Protein generated from TNT reactions (15 µL of each protein) were incubated per
reaction for 1 hour at room temperature. In a separate tube, protein G agarose beads (50
µL per reaction) were rinsed with 500 µL DPBS, pelleted at 10,000 rpm (8,161 x g) for
30 seconds and resuspended in DPBS supplemented with protease inhibitor cocktail
(PIC; Sigma) at 100 µL per reaction. Then, 10 µL of anti-p53 (FL393) or anti-Hdm2
(SMP14) antibody was added to 100 µL beads/DPBS mixture per reaction and rotated for
1 hour at room temperature. To the protein mixtures, 100 µL of DPBS/PIC was then
added. The bead/antibody mixture was combined with proteins and incubated rotating at
4°C overnight. The next morning the beads were pelleted at 10,000 rpm (8,161 x g) for
30 seconds followed by three wash steps using 500 µL of DPBS and pelleting beads at
10,000 rpm (8,161 x g) for 30 seconds between each wash. Proteins were eluted from
beads using 40 µL of 2X SDS loading dye (diluted from 6X SDS loading dye, see
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Western Blot for recipe) and heating the beads to 65°C for 2 minutes. Proteins were
analyzed by loading input (2.5 microliters of each protein per reaction) and eluted/coimmunoprecipitated material on a 12% SDS-PAGE gel following procedure described
under Western Blot.
Senescence Associated β-Galactosidase Assay
A β-galactosidase staining kit was purchased from Cell Signaling Technologies.
Cells were stained following the instructions supplied with the kit. Briefly, cells were
rinsed with 2 mL DPBS and fixed using 1X Fixation Buffer. Cells were then rinsed two
times using 2 mL DPBS. Cells were then stained by applying 1X Staining Solution and
incubating the cells at 37° C for 6-18 hours, as indicated. Staining Solution was then
removed, cells rinsed with 2 mL DPBS and stored in 70% glycerol at 4°C. Cells were
visualized under brightfield on an Olympus 1X70 fluorescence microscope at either
100X or 400X magnification. Images were captured using MagnaFIRE software. The
total number of cells and number of blue (β-galactosidase positive) cells were scored for
each image, making sure to score at least one hundred cells per treatment condition.
Scoring was confirmed by another member of the laboratory in a blinded fashion. The
percentage of β-galactosidase positive cells was determined for each treatment condition
which was normalized to transduction efficiency based on the percentage of GFP positive
cells (each average percentage of β-galactosidase positive cells divided by the percentage
of GFP positive cells). This process was completed in biological triplicate and the
average percent β-galactosidase positive cells normalized to transduction efficiency +/standard error of the mean were reported for each treatment condition.
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Senescence Associated Heterochromatin Formation (SAHF) Analysis
Cells previously processed with β-galactosidase stain were rinsed with DPBS
twice to remove the glycerol storage solution. Cells were then permeabilized with 0.2%
TritonX-100 in DPBS for 10 minutes at room temperature. Cells were washed once with
2 mL DPBS and the DNA stained with 25 µg/mL Hoechst dye (bis-Benzimide; Sigma)
for 5 minutes at room temperature. The cells were again washed with 2 mL DPBS and
stored in 70% glycerol at 4°C. Nuclei were visualized using fluorescence microscopy on
an Olympus 1X70 fluorescence microscope at 400X magnification. Images were
captured using MagnaFIRE software. The total number of nuclei and number of SAHF
containing nuclei were scored for each image, making sure to score at least one hundred
nuclei per treatment condition. Scoring was confirmed by another member of the
laboratory in a blinded fashion. The percentage of SAHF positive cells was determined
for each treatment condition which was normalized to transduction efficiency based on
the percentage of GFP positive cells, as described with percent β-galactosidase positive
reporting. This process was completed in biological triplicate and the average percent
SAHF positive cells normalized to transduction efficiency +/- standard error of the mean
were reported for each treatment condition.
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III. Results
The p53 and Hdm2 binding domains of HdmX are necessary for HdmX’s ability to block
oncogene induced senescence.
As previously described, HdmX/Hdm4 (mouse homologue MdmX/Mdm4)
negatively regulates p53 through binding and inhibiting p53’s transactivation domain
(Shvarts et al., 1996). HdmX is found to be over expressed in a significant number of
human tumors that express wild type p53, and it was determined that MdmX blocks
oncogene induced premature senescence in MEFs (Wade et al., 2009; Danovi et al.
2004). Due to the differences that exist between the murine and human cell culture
systems in the study of senescence, it was first necessary to confirm that HdmX can block
oncogene induced senescence in human diploid fibroblasts.
Human primary diploid fibroblasts (HDFs), specifically IMR90 cells, at passage
20 or younger were infected with H-RasG12V (H-Ras) which is a constitutively active
(GTP-bound) form of Ras protein previously reported to induce senescence in HDFs
(Serrano et al., 1997). The valine substitution in Ras renders the protein always in the
GTP-bound active state and allows Ras to function like an oncoprotein. Primary cell
lines do not transfect well; therefore, transductions (infections) using various viruses
were utilized to deliver genes to these cells. Each gene of interest (oncogenic H-RasG12V,
GFP, Hdm2, and HdmX) was cloned into a lentiviral vector and used for virus
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production. Titering of each viral construct was completed using a colony formation
assay which provided the number of infectious viral particles per mL (IVP/mL) and the
range of titers achieved are indicated in Table 4. IMR90 cells infected at a MOI
(multiplicity of infection) of 5 or higher achieved a transduction efficiency of 80% or
greater (data not shown), so all viruses were used at an MOI of 5 to ensure equal and
optimal infection.
Senescence-associated-β-Galactosidase (SA-β-Gal) activity at a pH of 6.0 is
measured by cleavage of an X-gal substrate allowing a blue dyed precipitate to form
which can be visualized within cells. This is the most widely used indicator of
senescence (Dimri et al., 1995). Acidic β-Galactosidase is a hydrolase located in the
lysosome, but the biological role for this enzyme during senescence is unknown. It has
been suggested that the increase in acidic β-Galactosidase activity reflects an increase in
the lysosomal mass of senescent cells (Kurz et al., 2000). While senescent cells have
stopped dividing, they still remain quite metabolically active and the active lysosomal
compartment is reflective of this property. Premature senescence measured by βGalactosidase staining was induced in approximately 50% of wild-type MEFs infected
with H-RasG12V and incubated for 8 days (Ferbeyre et al., 2002). A similar protocol
repeated in six independent experiments was used to measure premature senescence in
IMR90 cells.
Approximately 55% of the IMR90 cells transduced with H-RasG12V were
senescent (Figure 7). GFP was utilized as a negative control for viral infection and
induced senescence in a percentage of cells (7%) similar to no infection (complete media)
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Lentivirus

Infectious Viral Particles (IVP)/mL (range)

LGFP

104-105

LRas (H-RasG12V)

105-106

LHdmX

104-105

LHdm2

104-105

Table 4: Range of Titers for Lentiviral Supernatants. Infectious titers (IVP/mL)
were determined using a colony formation assay. The range of titers achieved for
each lentivirus is reported. Optimal titers reported by Invitrogen are between 105
and 106.
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(A)

(B)

CM

Ras + GFP

Ras

GFP

Ras + HdmX

Ras + Hdm2

Figure 7: HdmX Blocks H-RasG12V Induced Premature Senescence in Human
Diploid Fibroblasts. (A) Average % β-Galactosidase positive cells from 3
independent experiments +/- SEM per treatment condition normalized to transduction
efficiency determined by % GFP positive cells. (CM = complete media, Ras = HRasG12V). (B) Representative images from each treatment condition taken at 100X
magnification and same exposure time.
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treatment. GFP was also used along with H-RasG12V to compare single infections (HRasG12V) to double infections (H-RasG12V + GFP). The H-RasG12V + GFP infection is
similar to H-RasG12V alone indicating that infections with two viruses simultaneously can
be achieved without affecting senescence levels. The combination infection of HRasG12V with Hdm2 was also examined since Mdm2 overexpression has been indicated to
overcome growth arrest when co-introduced with other senescence inducers (Carnero et
al., 2000). Co-infection of H-RasG12V with HdmX was the experimental condition and
senescence was detected in 25% of these cells compared to GFP and H-RasG12V coinfection at 55% (Figure 7), suggesting that HdmX overexpression can block H-RasG12V
mediated senescence in HDFs. Hdm2 co-infected with H-RasG12V also blocked
premature senescence as expected. Expression of all constructs used with each treatment
was confirmed by Western blotting (Figure 8).
The results represented in Figure 7 indicate that HdmX over expression can block
oncogenic Ras induced premature senescence in human diploid fibroblasts, similar to
MEFs. Next, I set out to determine if the p53 and/or Hdm2 (Ring finger) binding
domains of HdmX are necessary for the ability of HdmX to block H-RasG12V mediated
senescence. In order to address this question, point mutations were created in HdmX that
were reported to inhibit its ability to bind p53 or Hdm2. MdmXG57A has been reported
by Danovi et al. (2004) to render MdmX unable to bind p53 and this amino acid is
conserved in HdmX. MdmXC437G was described by Sharp et al. (1999) as being unable
to bind Mdm2 and this residue is also conserved in HdmX. These two point mutations
were created using the QuikChange XL Site-Directed Mutagenesis Kit. DNA sequence
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Figure 8: Western Blot Analysis of IMR90 Transductions. IMR90 cells transduced
with no virus (CM), H-RasG12V (Ras), GFP, H-RasG12V (Ras) + GFP, H-RasG12V (Ras)
+ HdmX, H-RasG12V (Ras) + Hdm2, H-RasG12V (Ras)+HdmXG57A (XG57A) or HRasG12V (Ras) +HdmXC437G (XC437G) as described for Figure 7 and Figure 10.
Whole cell lysates were resolved by SDS-PAGE and analyzed by Western blotting for
indicated proteins.
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analysis was used to confirm successful mutagenesis for both mutations and that the
remainder of the HdmX cDNA was wild-type.
The activities of HdmXG57A and HdmXC437G were confirmed by coimmunoprecipitation using TNT generated proteins. Co-immunoprecipitations confirmed
that wild-type HdmX and HdmXC437G bound p53 while HdmXG57A was unable to do
so and that wild-type HdmX and HdmXG57A bound Hdm2 while HdmXC437G was
unable to do so (Figure 9). Together these results confirmed that the mutants were
functioning similar to wild-type with the exception of the predicted binding that was
disrupted by each single point mutation.
Infection of IMR90 cells with H-RasG12V induced senescence in approximately
55% of the cells in 7 days (Figure 7). Since binding to p53 is required for HdmX to
inhibit p53 transcriptional activity and functional p53 is required for senescence, it was
predicted that HdmXG57A would be unable to block H-RasG12V induced senescence.
This was confirmed through the senescence assay using IMR90 cells co-transduced with
H-RasG12V and HdmXG57A (Figure 10). Approximately 55% of IMR90 cells cotransduced with H-RasG12V and GFP senesced which is similar to cells co-transduced
with H-RasG12V and HdmXG57A. Both of these conditions are different from cells cotransduction of H-RasG12V and wild-type HdmX where only approximately 25% of the
cells senesced. As previously mentioned, HdmX and Hdm2 heterodimerization is also
important to p53 regulation. Hdm2, containing a nuclear localization sequence, has been
implicated in the shuttling of HdmX to the nucleus where it can interact and negatively
regulate p53 (Migliorini et al., 2002). Since HdmXC437G is unable to bind Hdm2, it is
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Figure 9: Characterization of HdmXG57A and HdmXC437G Mutants. Coimmunoprecipitations were completed using HdmX, Hdm2, HdmXG57A and
HdmXC437G proteins generated using Promega TNT Coupled Reticulocyte Lysate
System. Western blots demonstrating input proteins are shown in the top panel
(Input). Western blots from co-immunoprecipitated material are shown in the bottom
panel (IP).
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Figure 10: HdmX’s p53 and Hdm2 Binding Domains are Essential to Block HRasG12V Induced Premature Senescence in Human Diploid Fibroblasts.
Average % β-Galactosidase positive cells from three independent experiments +/SEM per treatment condition normalized to transduction efficiency determined by %
GFP positive cells. (CM = complete media, Ras = H-RasG12V).
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predicted that HdmXC437G will not block H-RasG12V mediated senescence. This was
also confirmed by the senescence assay where IMR90 cells co-transduced with HRasG12V and HdmXC437G senesced to a level similar to cells co-transduced with HRasG12V and GFP (approximately 50 and 55%, respectively) (Figure 10). Western blot
analysis confirmed expression of both HdmXG57A and HdmXC437G (Figure 8). It does
appear that HdmXC437G protein is less abundant when infected at the same MOI as
wild-type HdmX and HdmXG57A. This suggests that HdmXC437G may be more
unstable, which is likely since reports suggest that that MdmX:Mdm2 heterodimer is
more stable than either homodimeric form (Tanimura et al., 1999). This may, at least in
part, explain HdmXC437G’s inability to block H-RasG12V mediated senescence.
To further investigate why HdmXC437G was unable to block H-RasG12V
mediated senescence, a nuclear/cytoplasmic fractionation experiment was completed to
determine if HdmXC437G could localize to the nucleus in the presence of Hdm2.
Approximately 30% more wild-type HdmX and 25% more HdmXG57A localizes to the
nucleus in the presence of additional Hdm2 while HdmXC437G remains predominantly
cytoplasmic even with Hdm2 overexpression (Figure 11). These results support the idea
that HdmXG57A enters the nucleus but is unable to bind p53, which is reported to be
required for HdmX to inhibit p53 transactivation. HdmXC437G , however, appears to be
deficient at nuclear localization, which implies that this mutant is not reaching the
nucleus where it would interact with p53. Together these results suggest that HdmX
binding to p53 and Hdm2 are necessary for its ability to block H-RasG12V mediated
senescence.
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(A)

(B)

Figure 11: Wild-type HdmX and HdmXG57A Translocate to the Nucleus While
HdmXC437G Remains Cytoplasmic. IMR90 cells were transduced with wild-type
HdmX, HdmXC437G or HdmXG57A in addition to GFP (left panel) or Hdm2 (right
panel). (A) Cells were selected and then nuclear and cytoplasmic protein extracts
separated on an SDS-PAGE gel. Localization of Lamin A/C (a nuclear protein) and
Tubulin (a cytoplasmic protein) confirm the extract fractionation was effective. (B)
Bar graph represents nuclear/cytoplasmic ratios for HdmX proteins in the presence of
GFP or Hdm2 as quantified using Multiguage software. *Nuclear/cytoplasmic
fractionation and Western blot generated by Kevin Kelley.
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Reduction of HdmX in tumor cell lines with wild-type p53, mutated Ras and high levels
of HdmX triggers senescence.
It is known that HdmX over expression is found in many human tumors; however,
the mechanisms leading to and outcomes of HdmX over expression have not been fully
elucidated. It has also been indicated that many of the human tumors that over express
HdmX maintain wild-type p53. Interestingly, 90% of pancreatic, 50% of colon and
thyroid and 30% of all human tumors have mutated Ras (Saxena et al., 2008) which
makes the tumor phenotype of mutant Ras, wild-type p53 and high levels of HdmX
likely. Since HdmX can block oncogenic Ras induced senescence in untransformed
human diploid fibroblasts (Figure 7), knocking down HdmX in tumor cells with high
HdmX, mutant Ras and wild-type p53 may lead to tumor cell senescence.
To test this possibility, LNCaP cells, a prostate adenocarcinoma cell line with
wild-type p53, mutant Ras and high HdmX were utilized (Ramos et al., 2001). These
cells have been previously analyzed for their ability to senesce after various genetic
manipulations making them an attractive cell line for use in this study (Obajimi et al.,
2009; Baygi et al., 2010). Lentiviral short hairpin HdmX (shHdmX) and short hairpin
LacZ (shLacZ) vectors were used since short hairpin RNA interference (shRNAi)
technology is a highly efficient and specific method of silencing gene expression in cells.
Upon production of shHdmX and shLacZ lentivirus, LNCaP cells were infected
and knock-down of HdmX confirmed by Western blotting (Figure 12A). This sh-HdmX
construct was previously validated by Western blotting in our lab (K. Heminger, BMS
Thesis). A slight reduction of HdmX protein was detected in all lanes infected with any
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(A)
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Figure 12: Loss of HdmX Induces β-Galactosidase Activity in LNCaPs. (A)
LNCaP cells were transduced with no virus (CM), GFP, shLacZ (shL), HdmX/Rescue
(X/R), sh-HdmX (shX), shL+X/R, shX+X/R or shX+GFP, selected and whole cell
extracts were resolved by SDS-PAGE and subjected to Western blotting using
antibodies indicated. (B) Diagram demonstrating modulation of Hdm2-HdmX-p53
axis in response to cellular stress (Toledo et al., 2006). 1. Unstressed conditions
where p53 levels are kept low by Mdm2 (Hdm2) and Mdm4 (MdmX/HdmX). 2.
Stress causes induction of p53 by ubiquitination and degradation of Mdm4 and Mdm2
by Mdm2. 3. p53 drives expression of Mdm2 to increase Mdm2 levels. 4. Mdm2,
MdmX and p53 return to steady state levels. (C) Average % β-Galactosidase positive
cells normalized to transduction efficiency +/- standard error of the mean is reported
where >100 cells were counted per treatment condition (described in a) in three
biological replicates.
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short hairpin lentivirus, most likely due to a stress response and subsequent p53
activation in those cells leading to reduction of HdmX protein as a part of the p53HdmX-Hdm2 loop (Figure 12B). The nearly complete elimination of HdmX protein was
detected only in sh-HdmX infected cells. To confirm that any effect detected using shHdmX is a specific result of knock-down and not an off target effect from sh-HdmX
infection, HdmX protein levels were rescued in LNCaP cell using a Lentivirus-HdmX
expression vector harboring a silent mutation that makes the hdmX mRNA from this
cDNA resistant to the hdmX short hairpin RNA, which was also confirmed by Western
blot (Figure 12A).
LNCaP were infected with various lentivirus combinations as indicated in Figure
12 (C) followed by selection and incubation for approximately seven days. Cells were
then stained for β-Galactosidase activity. Reducing HdmX in LNCaP cells led to an
induction of senescence in approximately 58% of the cells and this level of senescence is
higher than sh-LacZ infected (approximately 18%) or complete media (CM) treated
(approximately 10%) cells (Figure 12C). Upon restoration of HdmX protein, there is a
decrease in senescence levels similar to background senescence levels (Figure 12C,
compare shLacZ to shX + HdmX/R, both approximately 18%). This finding supports
that the induction of senescence in LNCaP cells when HdmX is reduced is specifically
due to the decrease in HdmX protein.
To confirm that measurements of β-Galactosidase activity accurately represent
cellular senescence, SAHF analysis was performed on LNCaP cells infected with shHdmX and none were detected in β-Galactosidase positive or negative LNCaP cells.
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SAHF formation is a cell-type specific measurement of senescence induction; therefore,
they do not appear in all senescent cells. It was recently shown that epithelial tumor cells
treated with Nutlin-3a, and small molecule inhibitor of Mdm2, became β-Galactosidase
positive; however, upon drug removal, these some cells resumed proliferation (Huang et
al., 2009). So, it was important to determine if the β-Galactosidase staining that was
detected in LNCaP cells upon HdmX reduction was reversible. To address this issue, an
HdmX protein rescue/time course experiment was utilized.
LNCaP cells were infected with various lentiviral constructs as described in
Figure 13 followed by incubation under selection for 7 days, at which time a second viral
infection was completed to re-express HdmX protein levels in cells infected with shHdmX. After an additional 7 days of incubation under selection, all cells were subjected
to β-Galactosidase staining as previously described. Approximately 70% of the LNCaP
cells infected with only sh-HdmX were β-Galactosidase positive after 14 days which was
similar to cells infected with sh-HdmX initially followed by Rescue-HdmX infection at
day 7 (compare shX to shX : X/R in Figure 13A) suggesting that the increase in βGalactosidase positive cells detected after infection with sh-HdmX is NOT reversible and
represents a senescent state.
As in Figure 12C, shLacZ infection for 14 days induced senescence in about 20%
of the cells slightly higher than the GFP infection control at about 10%. Importantly,
cells initially infected with sh-HdmX and the rescue construct together only led to
approximately 13% of the cells undergoing senescence after 14 days, while about 68% of
the cells initially co-infected with sh-HdmX and GFP were induced to senesce. These
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Figure 13: Loss of HdmX Induces an Irreversible Increase in β-Galactosidase
Positive LNCaP Cells. (A) LNCaP cells were infected with no virus (CM), GFP,
shLacZ (shL), HdmX/Rescue (X/R), sh-HdmX (shX), shL+X/R, shX+X/R,
shX+GFP, shL, shX or shX and selection applied for 7 days. On day 7, shL infected
cells were additionally infected with X/R (shL:X/R), shX infected cells with X/R
(shX:X/R) and shX infected cells with GFP (shX:GFP) followed by an additional 7
days of incubation under selection. At day 14 all cells were subjected to betaGalactosidase staining. Histogram represents average % β-Galactosidase positive
cells normalized to transduction efficiency +/- standard error of the mean where
>100 cells were counted for each treatment condition in three independent
experiments. (B) Representative images of each treatment condition as described in
(A). All images taken at 100X magnification and the same exposure time. (C)
Western blot confirming HdmX protein rescue and knock-down in shX:X/R and
shX:GFP treatment conditions, respectively.
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results are similar to what is reported in Figure 12C for the 7 day time period. Initial coinfection of sh-LacZ and the rescue construct or sh-LacZ followed by the rescue protein
was again confirmed via Western blotting (Figure 13C). Together this data provides
evidence that targeting HdmX for cytoplasmic localization or reduction of total protein
can induce an irreversible state of cellular senescence in human tumors. Understanding
the dependency of mutant Ras and/or p53 on this induction of senescence will be a future
direction for this project.
YPEL3 Induces Cellular Senescence.
The focus previously was on activation of p53 and now I will describe a
downstream p53 target implicated in the senescence pathway. While much is known
about p53 targets involved in apoptosis and cell cycle arrest, those critical to senescence
induction are not as clearly defined. In studies where a cell cycle arrest of MCF7 cells
was induced by activating p53 via silencing its negative regulators HdmX or Hdm2,
novel p53 targets were discovered, one of which was YPEL3. YPEL3 was validated as a
specific p53 target through RT-PCR and ChIP analysis (Kelley et al., 2010).
Additionally, YPEL3 was reported to be growth suppressive potentially through the
apoptotic pathway in murine myeloid precursor cells (Baker, 2003).
To further investigate the role of human YPEL3, full-length human YPEL3 was
cloned from pCMV-SPORT6 vector (Open Biosystems) into the pLenti4/TO/V5/DEST
vector, which contains a tetracycline responsive promoter (TetOn, Invitrogen) and a V5
tag. Lentivirus was then produced with this construct and used to transduce MCF7
(breast carcinoma) and U2OS (osteosarcoma) cells that were stably expressing the
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Tetracycline Repressor protein (TetR). Colony formation assays were completed using
the aforementioned cells treated with 1 microgram/mL of Tetracycline to induce YPEL3
compared to transduced cells without the addition of Tetracycline, both for approximately
14 days (Figure 14A/B). There was a clear reduction in the number of colonies formed
when cells were treated with Tetracycline (approximately 50%) suggesting that YPEL3 is
also growth suppressive in human cells (Figure 14A and B).
To further confirm that YPEL3 is growth suppressive in human cells, MCF7TetR
and U2OSTetR expressing cells were infected with Tet-responsive YPEL3-V5 and stably
selected. These stable pooled populations will be referred to as MCF7TetR/YPEL3 and
U2OSTetR/YPEL3. Stable pools containing a Tet responsive LacZ expression vector
were also created for use as a negative control. YPEL3 and LacZ expression upon
Tetracycline induction was confirmed for U2OSTetR (Figure 15A) and MCF7TetR cell
lines (data not shown). After confirmation of proper protein expression, a cell viability
(MTT) assay was completed. U2OSTetR/YPEL3 cells induced with Tetracycline
demonstrated a 50% reduction in cell viability compared to U2OSTetR/YPEL3 cells not
treated with Tetracycline (Figure 15B). U2OSTetR/LacZ cells induced with Tetracycline
as a negative control only demonstrated an approximately 18% reduction in viability.
These results suggest that when expressed in human cells, YPEL3 is able to reduce cell
viability.
To further confirm that YPEL3 induction leads to growth suppression, RNAi
approaches were employed to knock down YPEL3 in MCF7 and U2OS cells (Figure 16).
Knock down of YPEL3 using two separate lentiviral shYPEL3 constructs was confirmed
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Figure 14: Induction of YPEL3 Leads to Growth Suppression in MCF7 and
U2OS Cells. (A) Representative images of colony formation assays of MCF7TetR
and U2OSTetR expressing cells transduced with Tet-inducible YPEL3-V5 (Zeocin
resistant) and treated with or without 1 microgram/mL Tetracycline (Tet). (B)
Percent colonies remaining +/- standard error of the mean in Tet treated cells
described in (A) compared to non-Tet treated cells (set to 100%) (Kelley et al.,
2010).
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Figure 15: Induction of YPEL3 Causes Reduction in Cell Viability. (A)
Western blot from whole cell lysates probed with anti-V5 antibody demonstrating
YPEL3/V5 and LacZ/V5 protein expression in U2OSTetR parental (lanes 1,2);
U2OSTetR/LacZ (lanes 3,4) and U2OSTetR/YPEL3 (lanes 5,6) cells treated with
(lanes 2, 4, 6) and without (lanes 1, 3, 5) 1 µg/mL tetracycline. (B) MTT assay of
cells as numbered and defined in (A) treated for 24 hours with or without
tetracycline. Each condition was performed in quadruplicate with error bars
representing standard error of the mean (MTT assay completed by Berberich, S.J.)
(Kelley et al., 2010)

55

Figure 16: RT-PCR Confirmation of YPEL3 Knock-down by RNAi in MCF7
Cells. Relative expression of YPEL3 normalized to GAPDH in MCF7 parental,
MCF7shYPEL3 (A), MCF7shYPEL3 (B) and MCF7shLacZ pooled stable cell lines.
Error bars represent 95% confidence intervals.
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by RT-PCR in MCF7 cells (Figure 16) and U2OS cells (with approximately 80% knock
down, data not shown). Upon confirmation of YPEL3 knock-down, MCF7shLacZ and
MCF7shYPEL3 (A) and (B) cells were plated at 50,000 cells per well in a six well dish.
Cell counts from each cell type were obtained using the ViCell at days two, four, and six
(Figure 17). MCF7shYPEL3 expressing cells grew at a faster rate than the shLacZ
control cells, indicating that the reduction of YPEL3 conferred a growth advantage in
MCF7 cells. Similar results were obtained using U2OS cells (data not shown). Together
these results further support the role of YPEL3 in growth suppression.
Since YPEL3 was shown to be up regulated in apoptotic myeloid precursor cells
and the induction of YPEL3 is associated with increase in Annexin V staining in these
cells, we initially investigated whether human YPEL3 was growth suppressive through
the apoptotic pathway in human cells. Interestingly, there was no indication that USOS,
MCF7 or LNCaP cells induced to express YPEL3 were undergoing apoptotic
programming as measured by PARP cleavage using doxorubicin treatment as a positive
control (data not shown). Based on the inability to detect apoptosis in U2OS and MCF7
cells induced to express YPEL3 and the unique morphologic characteristics of these cells,
I hypothesized that YPEL3 is growth suppressive through the cellular senescence
pathway. To address this hypothesis, established U2OSTetR and MCF7TetR stable
pooled cell lines were utilized and senescence was measured by β-Galactosidase staining
and SAHF analysis, as previously described.
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Figure 17: RNAi Targeting YPEL3 Leads to Increased Cellular Proliferation.
Pooled populations of MCF7 cells stably infected with either shLacZ (diamonds) or
one of two shRNAs targeting YPEL3 (shYPEL3-A, squares; shYPEL3-B, triangle)
were plated at 50,000 per 6 well dish. Two days later, 3 wells per cell line were
separately counted using a ViCell cell viability counter (Day 2). Cell counts were
repeated on days 4 and 6. Average cell number +/- standard deviation is reported for
each cell type on each day counted. Experiment was repeated with similar results.
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U2OSTetR/YPEL3, U2OSTetR/LacZ and U2OSTetR parental cells were plated
in duplicate in six well dishes. For each cell type, one well was induced with
Tetracycline at 1 µg/mL and the other with complete media. At the end of 6 days, the
plate was subjected to β-Galactosidase staining as previously described. Images were
taken of each treatment condition and representative images are shown in Figure 18A.
Approximately 30% of the YPEL3 expressing U2OS cells were β-Galactosidase positive,
as indicated by the blue positive staining (Figure 18B). This level of senescence was
higher than the LacZ expressing control cells which were approximately 8% βGalactosidase positive (Figure 18B). Together this suggests that YPEL3 induction
triggers senescence in U2OS osteosarcoma cells.
To confirm that the senescence induction following an increase of YPEL3 was not
specific to the U2OS cell type, MCF7 breast carcinoma cells were analyzed as described
in Figure 18. MCF7 cells demonstrated the same phenotype where 25% of the YPEL3
expressing and only 8% of the LacZ expressing cells scored β-Galactosidase positive
(Figure 19). Together these results suggest that the senescence induced by YPEL3 is not
specific to only U2OS cells and that the growth suppression that occurs due to YPEL3
induction is likely occurring through the induction of senescence as measured by an
increase in β-Galactosidase activity.
As mentioned previously, Huang and colleagues described a Nutlin-dependent
cell cycle arrest that resulted in reversible increase in β-Galactosidase staining in
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Figure 18: Increase of YPEL3 Triggers Cellular Senescence in U2OS Cells as
Measured by β-Galactosidase Staining. (A) Representative images of U2OSTetR
(UTR), U2OSTetR/LacZ (UTR/LacZ) and U2OSTetR/YPEL3 (UTR/YPEL3) cells
induced with 1 µg/mL of Tetracycline for 6 days and subjected to beta-Galactosidase
staining. Images taken at 100X magnification and same exposure time. (B)
Histogram representing the average % β-Galactosidase positive cells per treatment
condition +/- standard error of the mean of at least 100 cells counted per treatment
condition in biological triplicate. (Kelley et al., 2010)
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Figure 19: Induction of YPEL3 Triggers Senescence in MCF7 Cells as Measured
by β-Galactosidase Staining. Representative images of MCF7TetR parental (A),
MCF7TetR/LacZ (B) and MCF7TetR/YPEL3 (C) cells induced with 1 µg/mL
Tetracycline for 6 days followed by β-Galactosidase staining. Images taken at 100X
magnification and same exposure time. Histogram represents average % betaGalactosidase positive of at least 100 cells scored per treatment condition. (Kelley et
al., 2010)
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epithelial tumor cells (Huang et al., 2009). Senescence, by definition, is an irreversible
process; therefore, the use of β-Galactosidase staining as a sole measurement of
senescence has been questioned. To ensure that the increase in β-Galactosidase staining
seen with the induction of YPEL3 is in fact an indication of senescence in these cells,
senescence associated heterochromatin formation (SAHF) was examined. SAHFs appear
as permanent chromatin condensation occurs in senescent cells, as previously described
(Figure 2).
U2OSTetR/YPEL3, U2OSTetR/LacZ and U2OSTetR parental cells treated as
described in Figure 18 were subjected to Hoechst dye staining followed by fluorescence
microscopy. Hoechst dye is a fluorescent stain used for labeling DNA and allows for the
detection of punctuate foci within the nucleus upon SAHF formation. Representative
images of this analysis are shown in Figure 20A. Notice the uniform staining of the
DNA within the LacZ expressing control nuclei (left panels) and the punctuate foci
within the nuclei of the YPEL3 expressing SAHF positive cells (right panels). The
percentage of SAHF positive cells in YPEL3 expressing U2OS cells was similar to the
percentage β-Galactosidase positive cells (approximately 28% and 30%, Figure 20B and
18B, respectively). SAHF detection provides further support that YPEL3 functions as a
senescence inducer in human tumor cell lines. More importantly, the presence of SAHFs
confirms that these cells are not reversibly β-Galactosidase positive since SAHF
formation and associated silencing of E2F target genes do not occur in reversibly arrested
cells (Narita et al., 2003).
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Figure 20: YPEL3 Induces Senescence in U2OS Cells as Measured by SAHFs.
(A) Representative images of U2OSTetR/LacZ (left) and U2OSTetR/YPEL3 (right)
cells incubated with 1 µg/mL Tetracycline for 6 days followed by Hoechst dye
(images on left in set of 4) and beta-Galactosidase (images on right in set of 4)
staining. Images taken at 400X magnification and same exposure time. (B)
Histogram representing the average % SAHF positive cells per treatment condition
+/- standard error of the mean of at least 100 cells counted per treatment condition in
biological triplicate. (Kelley et al., 2010)
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In order to confirm that the induction of senescence by YPEL3 was not unique to
tumor cell lines, non-transformed human diploid fibroblasts (IMR90 cells) were utilized.
As previously mentioned, oncogenic Ras is known to induce senescence in IMR90 cells
and served as a positive control inducing senescence, as measured by β-Galactosidase
activity and SAHF formation in approximately 75% of the cells (Figure 21B). GFP
served as a negative control for viral infection and only about 18% of the cells scored
positive for β-Galactosidase activity or SAHF formation. Approximately 45% and 65%
of the IMR90 cells transduced with YPEL3 scored positive for β-Galactosidase staining
and SAHF formation, respectively. Together these results suggests that elevated YPEL3
is sufficient to induce senescence in a non-transformed cell line and further supports the
conclusion that human YPEL3 is growth suppressive through the induction of cellular
senescence.
YPEL3 Functions Downstream of p53 During H-RasG12V Mediated Senescence.
As previously stated, oncogenic Ras-induced premature senescence requires
functional p53. Yet, downstream targets of p53 that are necessary for senescence have
been difficult to identify. Uncovering critical targets and regulatory proteins involved in
the p53 pathway leading to senescence would provide useful targets for anti-cancer drug
design. It is clear that YPEL3 is a p53 target and is sufficient to induce senescence in
human diploid fibroblasts (Figure 21) along with human tumor cells lines, as described
previously. However, it is unclear where YPEL3 fits within the senescence pathway.
The induction of senescence in human diploid fibroblasts (IMR90 cells) by H-RasG12V
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Figure 21: YPEL3 is Sufficient to Induce Senescence in Human Diploid
Fibroblasts. (A) IMR90 cells transduced with empty virus (CMV), YPEL3-V5 or
Ras (H-RasG12V = H-ras) were incubated for 7 days followed by β-Galactosidase (left
panel) and Hoechst dye (right panel) staining. Brightfield and fluorescence images
taken at 400X magnification and same exposure time for each. (B) Histogram
represents % positive cells where over 100 cells were counted for each treatment
condition described in (A) normalized to transduction efficiency based on GFP
positive cells. (Kelley et al., 2010)
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was used as a model system to begin to probe the location of YPEL3 within the
senescence pathway.
First, to ensure that the use of oncogenic Ras mediated senescence in IMR90 cells
was a good model system for the study of YPEL3, the expression profile of YPEL3
during H-RasG12V mediated senescence was investigated using RT-PCR analysis. This
was achieved by following a time course protocol where H-RasG12V virus was transduced
into IMR90 cells followed by daily RNA isolations and RT-PCR analysis for senescence
associated genes as described by Mason and colleagues (2004). IMR90 cells were
transduced with H-RasG12V virus following the time course described in Figure 22A. As
previously reported, expression of p21, a known p53 target and senescence associated
gene, was elevated at day 3 and again at day 6 post-infection (PI) (Mason et al., 2004).
Interestingly, YPEL3 expression followed a similar pattern of induction at day 3 and day
6 PI. The feeding schedule was monitored and resulting increase in mitogenic activity
correlating with fresh complete media addition was not the basis for this particular
pattern of gene expression. Furthermore, the induction of senescence has also been
described as a dynamic process (Young et al., 2009). The periodic induction of p21 as
reported by Mason and colleagues along with YPEL3, described in this study, suggests
that molecular targets of senescence may be transiently induced as the cell reprograms to
an irreversibly arrested state (Mason et al., 2004; Kelley et al., 2010). These results
supported the use of H-RasG12V mediated senescence as a tool for studying how YPEL3
induces senescence.
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Figure 22: YPEL3 is Induced During H-RasG12V Mediated Senescence in
IMR90s. (A) Schematic diagram representing infection and antibiotic (Blasticidin)
selection schedule for IMR90 cells transduced with lentivirus expressing H-RasG12V
(Mason et al., 2004). (B) RT-PCR analysis of YPEL3 and p21 expression
normalized to GAPDH from cells described in (A) at time points indicated. Error
bars represent 95% confidence intervals. (Kelley et al., 2010)
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Previous data supports that YPEL3 is a p53-target and sufficient to induce
senescence in IMR90 cells, but it is unclear whether YPEL3 is a critical p53 target
required in IMR90 cells for H-RasG12V mediated senescence. To determine if YPEL3
expression is required for oncogene-induced senescence, the knock-down of YPEL3
using two different short-hairpin vectors (shYPEL3(A) and shYPEL3(B)) alone and in
combination with H-RasG12V transduction were completed. β-Galactosidase staining and
SAHF analysis were utilized to measure senescence, as described previously. Reduction
of YPEL3 was confirmed at the mRNA level. Knock down in cells infected with
shYPEL3 virus was confirmed by RT-PCR analysis (Figure 23). YPEL3 expression in
shYPEL3 infected cells was only 30% that of IMR90 cells infected with shLacZ.
Evaluation of endogenous YPEL3 protein level is difficult due to its rapid turnover
through the ubiquitin-proteasome pathway (data not shown).
Upon confirmation of YPEL3 knock-down, IMR90 cells were transduced with HRasG12V alone and in combination with shLacZ (negative control) or one of the YPEL3
short-hairpin viruses. Co-transduction of H-RasG12V and shLacZ produced senescence
levels similar to H-RasG12V infection alone, demonstrating that infection with a short
hairpin vector did not impact senescence (Figure 24). When endogenous YPEL3 levels
are lowered using shYPEL3 (A) or shYPEL3 (B), H-RasG12V was only able to induce
senescence in approximately 25% and 10% of the cells as measured by β-Galactosidase
activity, respectively (Figure 24A). These levels are lower than control senescence levels
of approximately 65% (H-RasG12V + shLacZ) suggesting that reducing YPEL3 blocks HRasG12V mediated senescence in IMR90 cells. Results from the β-Galactosidase activity
assay were supported by SAHF detection in cells transduced as described previously
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Figure 23: RT-PCR Confirmation of YPEL3 Knock-down by RNAi in IMR90
Cells. IMR90 cells uninfected (CM) or infected with shLacZ, shYPEL3 (A) or
shYPEL3 (B) followed by selection were analyzed for YPEL3 mRNA levels
normalized to GAPDH by RT-PCR. Error bars represent 95% confidence
intervals (RT-PCR completed by Rebecca Tuttle, MD).
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Figure 24: Loss of YPEL3 Blocks H-RasG12V Mediated Senescence in IMR90s.
Histograms represent average % β-Galactosidase (A) or SAHF (B) positive cells
where over 100 cells were counted for each transduction condition of IMR90 cells
listed on X-axis (Ras=H-RasG12V). Averages normalized to transduction efficiency
based on % GFP positive cells from three biological replicate experiments. Error
bars represent standard error of the mean.
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(Figure 24B), suggesting that YPEL3 is a critical downstream p53 target during HRasG12V mediated senescence in IMR90 cells.
It is reported that p53 is required for oncogenic Ras induced senescence (Serrano
et al., 1997) and that YPEL3 is a direct p53 target (Kelley et al., 2010). Combined with
the result that YPEL3 is sufficient to induce senescence in IMR90 cells, I hypothesized
that YPEL3 is functioning downstream of p53 during H-RasG12V mediated senescence.
To address this issue, RNAi targeting p53 was used to block H-RasG12V mediated
senescence combined with the addition of YPEL3 followed by senescence analysis as
previously described. The use of shLacZ and GFP transductions were utilized as
negative controls for shp53 and YPEL3, respectively. Knock-down of p53 was
confirmed by Western blotting in IMR90 cells (Figure 25).
It is clear that transduction of IMR90 cells with oncogenic H-RasG12V (A) and
YPEL3 (C) induces senescence in approximately 70% of the cells and this senescence
level is higher than that achieved with the negative control GFP (B) at approximately
12% (Figure 26). The combination of H-RasG12V and GFP (D) served as a control for
transduction of additional viruses with H-RasG12V and senescence levels for this treatment
condition remain the same as H-RasG12V alone. Co-infection of H-RasG12V and YPEL3
(E) lead to senescence levels the same as H-RasG12V (A) suggesting that the two may be
functioning through the same pathway or there is simply a threshold of senescence that is
reached with H-Ras or YPEL3 alone, therefore, combining them does not provide a
further increase in senescence level.
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Figure 25: Western Blot Confirmation of p21, p53 and p16 Knock-down by
RNAi in IMR90 Cells. IMR90 cells uninfected (CM) or infected with sh-control
(shcon), shp21, shp53 or shp16 followed by selection were resolved by SDS-PAGE
and subjected to Western blot analysis using antibodies indicated on right.
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Figure 26: YPEL3 Functions Downstream of p53 During H-RasG12V Mediated
Senescence in Human Diploid Fibroblasts as Measured by β-Galactosidase
Staining. (A) Histogram represents average % β-Galactosidase positive cells where
over 100 cells were counted for each transduction of IMR90 cells with (A) Ras (HRasG12V) (B) GFP (C) YPEL3 (D) Ras+GFP (E) Ras+YPEL3 (F) Ras+shp53 (G)
Ras+shp53+YPEL3 (H) Ras+shLacZ followed by incubation under selection for 7
days. Averages normalized to transduction efficiency based on % GFP positive cells
(averaged from B and D) from three biological replicate experiments. Error bars
represent standard error of the mean. (B) Representative images of treatment
conditions described in (A) taken at same exposure time and 100X magnification.
(Kelley et al., 2010)
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When p53 levels were knocked down with H-RasG12V transduction (F), levels of
senescence in IMR90 cells were lower (approximately 23%) than co-transduction of HRasG12V and shLacZ (H) at approximately 68%, confirming that p53 is required for HRasG12V mediated senescence in IMR90 cells. Interestingly, when YPEL3 is induced
when p53 levels are knocked down with H-RasG12V infection (G), senescence levels
return to levels similar to H-RasG12V infection alone. Together these results indicate that
YPEL3 is functioning downstream of p53 in the induction of senescence in IMR90 cells
by oncogenic Ras or parallel to p53 regardless of p53 levels.
To provide further support for the results obtained with the β-Galactosidase
activity assay, SAHF analysis was completed under the same transduction conditions as
described in Figure 26. As expected, the senescence levels measured by the percentage
of SAHF positive cells (Figure 27) were similar to those observed using β-Galactosidase
staining (Figure 26). This confirms that YPEL3 is functioning downstream of p53 in the
H-RasG12V induced senescence pathway in non-transformed human fibroblasts.
Additionally, the reduction of YPEL3 or p53 blocking H-RasG12V mediated senescence
while YPEL3 rescues senescence blocked by reduction of p53 suggests that YPEL3 is a
critical, downstream p53 target required for H-RasG12V mediated senescence.
To further investigate the mechanism through which YPEL3 is functioning as a
senescence inducer, other key senescence related proteins, p16 and p21, were reduced in
combination with H-RasG12V, YPEL3 or H-RasG12V and YPEL3 infection, followed by βGalactosidase staining. p16 represents a direct link to the Rb arm of the senescence
pathway and p21 is a link from the p53 pathway to the Rb pathway. p21 is a known p53
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Figure 27: SAHF Analysis Confirms that YPEL3 Functions Downstream of p53
During H-RasG12V Mediated Premature Senescence. (A) Histogram represents
average % SAHF positive cells where over 100 cells were counted for each
transduction of IMR90 cells with (A) Ras (H-RasG12V) (B) GFP (C) YPEL3 (D)
Ras+GFP (E) Ras+YPEL3 (F) Ras+shp53 (G) Ras+shp53+YPEL3 (H) Ras+shLacZ
followed by incubation under selection for 7 days. Averages normalized to
transduction efficiency based on % GFP positive cells (averaged from B and D)
from three biological replicate experiments. Error bars represent standard error of
the mean. (B) Representative images of treatment conditions described in (A) taken
at same exposure time and 400X magnification. (Kelley et al., 2010)
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target that is induced as cells undergo senescence and loss of p21 in human diploid
fibroblasts allows them to bypass senescence programming (Brown et al., 1997).
Additionally, loss of p16 allows for the block of oncogenic Ras mediated senescence in
human diploid fibroblasts indicating the importance of the p16 arm of the senescence
pathway in human cells (Brookes et al., 2002). Western blot analysis confirming knockdown of p16 and p21 using their respective short hairpin lentiviruses are demonstrated in
Figure 25.
Infection of IMR90 cells with H-RasG12V induced senescence in approximately
55% of the cell and reducing levels of p16 or p21 blocked H-RasG12V mediated
senescence as previously reported (Figure 28A). Interestingly, YPEL3 expression which
is confirmed by RT-PCR (Figure 28B) rescued H-RasG12V mediated senescence blocked
by reducing p16 but not p21. Future studies will be aimed at determining this
discrepancy. H-RasG12V mediated senescence is carried out through complex signaling
cascades and the inability of YPEL3 to rescue senescence blocked by lowering p21 may
be explained through one of the many Ras mediated signaling cascades.
As previously indicated, YPEL3 induced senescence in IMR90 cells as measured
by β-Galactosidase staining in approximately 58% of the cells (Figure 29A). When coinfected with shLacZ (control), shp16 or shp21, YPEL3 was still able to induce
senescence in a similar percentage of IMR90 cells (approximately 57, 57 and 58%,
respectively) while only 5-10% of the IMR90 cells scored β-Galactosidase positive when
infected with no virus, GFP, shLacZ, shp16 or shp21 alone as controls. Validation of p16
and p21 knock down at the protein level in IMR90 cells using shp16 and shp21,
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Figure 28: YPEL3 Rescues H-RasG12V Mediated Senescence Blocked by
Decrease of p16 but Not p21. (A) Histogram represents average % β-Galactosidase
positive cells where over 100 cells were counted for each transduction of IMR90
cells with no virus (CM), Ras (H-RasG12V), GFP, Ras+shL(shLacZ), Ras+shp16,
Ras+shp21, Ras+shLacZ+YPEL3, Ras+shp16+YPEL3 or Ras+shp21+YPEL3
followed by incubation under selection for 7 days. Averages normalized to
transduction efficiency based on % GFP positive cells from three biological replicate
experiments. Error bars represent standard error of the mean. IMR90 cells
uninfected (CM) or infected as in (A) were analyzed for YPEL3 (B) or p21 (C)
mRNA levels normalized to GAPDH by RT-PCR. Error bars represent 95%
confidence intervals (RT-PCR completed by Rebecca Tuttle, MD).
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Figure 29: YPEL3 Functions Independent of p16 or p21 as a Senescence
Inducer. (A) Histogram represents average % β-Galactosidase positive cells where
over 100 cells were counted for each transduction of IMR90 cells with no virus
(CM), GFP, YPEL3, shLacZ, shp16, shp21, YPEL3+shLacZ, YPEL3+shp16 or
YPEL3+shp21 followed by incubation under selection for 7 days. Averages
normalized to transduction efficiency based on % GFP positive cells from three
biological replicate experiments. Error bars represent standard error of the mean.
IMR90 cells uninfected (CM) or infected as in (A) were analyzed for YPEL3 (B) or
p21 (C) mRNA levels normalized to GAPDH by RT-PCR. Error bars represent 95%
confidence intervals (RT-PCR completed by Rebecca Tuttle, MD).
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respectively, is shown in Figure 25. Expression of YPEL3 in treatment conditions where
YPEL3 was infected is confirmed at the mRNA level by RT-PCR and is between 20 and
30 fold higher than control levels for each infection (Figure 29B). These results reinforce
that expression of YPEL3 alone is sufficient to induce senescence in IMR90 cells and
that this senescence is independent of p16 or p21 expression in these cells.
The addition of β-estradiol decreases YPEL3 expression in MCF7 Cells.
The estrogen receptor has been demonstrated to regulate p53 target genes through
the presence of an estrogen response element next to a p53 response element (Menedez et
al., 2007). Additionally, ERα was shown to bind directly to p53 and repress its function
(Liu et al., 2006). YPEL3 has been described as a direct p53 target (Kelley et al., 2010),
however, there is no predicted estrogen response element within the promoter region of
YPEL3. It remains unknown whether ER signaling plays any role in regulation of
YPEL3 gene expression, potentially through the interaction of p53 and ERα.
Interestingly, a decrease in YPEL3 expression has been observed in breast tumor samples
that contain ER negative status (personal communication R. Tuttle, MD). Taken
together, this suggests that YPEL3 may be regulated through estrogen receptor signaling
in a p53 dependent manner. Since YPEL3 is a direct p53 target, the hypothesis I tested is
that expression of YPEL3 decreases in response to estrogen in ER+, wild-type p53 breast
carcinoma cells.
To begin to investigate the role of the estrogen receptor in YPEL3 gene
regulation, MCF7 breast carcinoma cells (ER+, wild-type p53) were incubated in
complete media (CM) or charcoal stripped serum (CSS) for 48 hours followed by RNA
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isolation and RT-PCR analysis (Figure 30). CSS is media that has been treated with
activated carbon to remove non-polar materials such as certain growth factors, hormones
and cytokines (purchased from Invitrogen) and served as a mechanism for estrogen
removal. Expression of YPEL3 mRNA increased 4-fold accompanied by a
corresponding increase in YPEL3 protein when MCF7 cells were treated with CSS
compared to cells in CM suggesting that YPEL3 may at least indirectly be regulated by
estrogen signaling (Figure 30). (RT-PCR analysis for the study of YPEL3 regulation by
the estrogen receptor was completed by Rebecca Tuttle, MD).
To investigate the dependence of this increase in YPEL3 expression upon
estrogen depletion, SKBr3 cells were utilized. These cells are ER- and have a gain-of
function mutant p53. When incubated in CM or CSS for 48 hours there was no change
detected in YPEL3 expression in these cells (Figure 31) supporting that it may in fact be
estrogen receptor signaling that is responsible for the increase in YPEL3 expression after
estrogen depletion. Since charcoal stripping serum removed all steroid hormones, adding
back 17-β-estradiol (Sigma) to cells incubated in CSS allowed for the determination of
gene expression modulation due specifically to estrogen removal. 17-β-estradiol (βestradiol; beta-Estradiol; E2) is the most potent, active form of the estrogen hormones. It
serves as the most predominant sex hormone in females and is shown to induce
transformation and tumorigenesis in human breast epithelial cells (Russo et al., 2006).
MCF7 cells were incubated in CSS for 24 hours prior to treatment with vehicle
control (VC) or 17-β-estradiol (E2). The addition of 1nM β-estradiol to MCF7 cells
reduced expression of YPEL3 approximately 50% compared to MCF7 cells incubated in
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Figure 30: Expression of YPEL3 in MCF7 Cells Increases in Charcoal Stripped
Serum. (A) RT-PCR analysis of YPEL3 expression normalized to GAPDH in MCF7
cells incubated in complete media (CM) or charcoal stripped media (CSS) for 48 hrs.
Error bars represent 95% confidence intervals. (B) Protein was isolated from cells
treated for 48 hours in CM or CSS followed by the addition of MG132 for the last 4
hours and resolved on a tricene gradient (low acrylamide concentration) gel followed
by Western blotting. Antibodies used are indicated to the right of each image.
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Figure 31: Expression of YPEL3 Is Unchanged in Charcoal Stripped Serum in
an ER Negative Cell Line. RT-PCR analysis of YPEL3 expression normalized to
GAPDH in SKBr3 cells incubated in complete media (CM) or charcoal stripped
media (CSS) for 48 hrs. Error bars represent 95% confidence intervals.
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CSS (Figure 32). This same concentration of β-estradiol produced a 2.5-fold increase in
pS2 expression, which was used as a positive control in this experiment since pS2 is a
known estrogen positively regulated gene. Increasing concentrations of β-estradiol did
not further decrease the expression of YPEL3 or increase the expression of pS2
suggesting that 1 nM estradiol is a saturating dose for regulating gene expression of
YPEL3 or pS2. This data supports the previous finding that YPEL3 may be regulated
through the estrogen receptor and suggests that activation of the estrogen receptor by βestradiol works to decrease YPEL3 expression in MCF7 cells.
Next, Tamoxifen was used to specifically block the interaction of estrogen with
the estrogen receptor and further examine the regulation of YPEL3 expression.
Tamoxifen is widely used clinically in the treatment of women with ER+ breast tumors
for its ability to block the interaction of estrogen with the estrogen receptor (Osborne,
1998). MCF7 cells were incubated in CSS for 48 hours and showed a 3-fold increase in
YPEL3 mRNA and a slight decrease in pS2 mRNA, as previously reported (Figure 32).
The addition of 1 nM β-estradiol (E2) blocked the increase in YPEL3 or decrease in pS2
mRNA seen in CSS alone. More importantly, the further addition of 10 µM Tamoxifen
to CSS+E2 reversed the E2 effects allowing a partial increase in YPEL3 and decrease in
pS2 expression. Together, this data supports that YPEL3 gene expression is inhibited by
estrogen, potentially through the estrogen receptor.
To address the p53 dependence of the increase of YPEL3 expression following
estrogen removal, MCF7shp53 and MCF7shCON cell lines were generated. Knock
down of p53 at the mRNA and protein level in the MCF7shp53 stable pools was
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Figure 32: Decrease of YPEL3 Expression in MCF7 Cells Treated with βestradiol is Partially Blocked by Tamoxifen. (A) RT-PCR analysis of YPEL3 and
pS2 expression normalized to GAPDH in MCF7 cells incubated in charcoal stripped
media (CSS) for 24 hrs followed by treatment with vehicle control (ethanol) or βestradiol (Estradiol) for 24 hrs. Error bars represent 95% confidence intervals. 4.1
µl ethanol represents highest volume used for β-estradiol administration and is used
for VC. (B) RT-PCR analysis of YPEL3 and pS2 expression normalized to
GAPDH in MCF7 cells incubated in complete media (CM) or charcoal stripped
media (CSS) for 24 hrs followed by treatment with indicated Tamoxifen (Tam; µM)
and/or β-estradiol (E2; nM) in CSS for 24 hrs. Error bars represent 95% confidence
intervals.
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confirmed via RT-PCR and Western blotting (Figure 33A/B). MCF7shp53 and
MCF7shCON cells were grown in CM or CSS. There was a similar increase in YPEL3
expression, approximately 3 fold and 3.5 fold in MCF7shCON and MCF7shp53 cells,
respectively, in cells grown in CSS for 48 hours (Figure 33C). The expression of p21
was also monitored to determine if CSS incubation was inducing a p53 stress response
and p21 expression was not modulated by incubation in CSS in either cell line,
supporting the p53 independence of the increase in YPEL3 expression upon estrogen
depletion (Figure 33C). These findings suggest that the increase in YPEL3 expression
upon estrogen depletion is independent of p53.
To determine if estrogen repression of YPEL3 was dependent on ERα signaling, a
similar approach was utilized wherein ERα was knocked down using RNAi in MCF7
cells, followed by incubation in CM or CSS and RT-PCR analysis of YPEL3 expression.
MCF7shERα stable pooled cells were unable to be maintained; therefore, MCF7 cells
were infected in shCON or shERα lentivirus at an MOI of 5. MCF7 cells infected with
shCON exhibited the same expression profile as seen with parental cells when incubated
in CSS for 48 hours with an approximate 2.8-fold increase in YPEL3 mRNA and slight
reduction of pS2 mRNA (Figure 34). MCF7 cells infected with shERα and grown in CM
also demonstrated a 3-fold increase in YPEL3 mRNA. Therefore, cells grown in the
absence of estrogen or ERα both demonstrate an elevation of YPEL3 mRNA, suggesting
that it is the cooperation of estrogen with ERα that is allowing for the observed change in
YPEL3 expression. Reduction of ERα was confirmed at the mRNA and protein levels
(Figure 34).
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Figure 33: Increase in YPEL3 Expression Following Estrogen Depletion is
Independent of p53. (A) RT-PCR analysis of p53 expression normalized to
GAPDH in MCF7shCON and MCF7shp53 pooled, stable cells lines. Error bars
represent 95% confidence intervals. (B) MCF7 parental, MCF7shCON and
MCF7shp53 cells were treated without or with 0.5 μM doxorubicin overnight and
whole cell extracts were resolved by SDS-PAGE and subjected to Western blotting.
(C) RT-PCR analysis of YPEL3, pS2 and p21 expression normalized to GAPDH in
MCF7shCON and MCF7shp53 cells incubated in CM or charcoal stripped media
(CSS) for 48 hours. Error bars represent 95% confidence intervals.
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Figure 34: Increase in YPEL3 Expression Following Estrogen Depletion is
Dependent on ERα. (A) RT-PCR analysis of YPEL3, pS2 and ER expression
normalized to GAPDH in MCF7 cells infected with shCON or shER at an MOI of
5 and incubated in CM or CSS for 48 hours. Error bars represent 95% confidence
intervals. (B) Whole cell extracts prepared from cells treated as in (A) were
resolved by SDS-PAGE and subjected to Western blotting.
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Removal of Estrogen Induces YPEL3-Dependent Senescence in MCF7 Cells.
Tamoxifen has been indicated to trigger a G0/G1 cell cycle arrest in ER+ breast
tumors (Osborne, 1998). It has also been shown that the addition of estrogens can relieve
the G0/G1 cell cycle block of MCF7 cells after treatment with Tamoxifen (Planas-Silva, et
al., 1997). Additionally, over expression of YPEL3 was shown to induce senescence in
MCF7 cells (Figure 19) and removal of estrogen by charcoal stripping the serum was
shown to increase YPEL3 expression in MCF7 cells 4-fold compared to cells in complete
media (Figure 30). Together this information led to the hypothesis that removal of
estrogen from MCF7 cells would increase YPEL3-dependent senescence.
To address this hypothesis, wild-type MCF7 cells along with pooled stable
populations of MCF7shLacZ and MCFshYPEL3 (A) and (B) cells characterized in
Figure 16 were utilized. MCF7 cells were incubated in CM, CSS, or CSS plus 1 nM βestradiol (E2) for 6 days followed by β-Galactosidase staining (Figure 35A).
Approximately 80% of the cells grown in CSS scored β-Galactosidase positive compared
to approximately 12% of the cells in CM (Figure 35A). Since charcoal stripping the
serum removes many hormones, growth factors and cytokines from the system, adding
back of 1 nM estradiol allowed for investigation of the estrogen specific effects. When
cells were incubated in CSS + 1 nM estradiol, the percentage of β-Galactosidase positive
cells returned to approximately 35% indicating that the increase in β-Galactosidase
staining upon treatment of cells in CSS was partially due to the removal of estrogen
(Figure 35A). The addition of higher concentrations of estradiol (up to 100 nM) returned
the percentage of β-Galactosidase positive cells to control level (Figure 35C).
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Figure 35: Removal of Estrogen Triggers YPEL3-Dependent Senescence in
MCF7 Cells as Measured by β-Galactosidase Staining. (A and B) Top:
Histogram representing the average % β-Galactosidase positive cells per treatment
condition +/- standard error of the mean of at least 100 cells counted per treatment
condition in biological triplicate. Cells were incubated for 6 days in indicated
media. Bottom: Representative images of cells treated as in top histogram. Images
taken at 100X magnification and same exposure time. (C) Histogram representing
the average % β-Galactosidase positive cells per treatment condition of at least 100
cells counted per treatment condition. Cells were incubated for 6 days in indicated
media.
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Next, the role of YPEL3 in the induction of senescence of MCF7 cells upon
estrogen depletion was investigated. MCF7shLacZ, MCF7shYPEL3(A) and
MCF7shYPEL3(B) pooled, stable cell populations were incubated in CM or CSS for 6
days followed by β-Galactosidase staining as previously described for parental MCF7
cells. Approximately 58% of MCF7shLacZ expressing control cells scored βGalactosidase positive when incubated in CSS for 6 days (Figure 35B).
MCF7shYPEL3(A) and MCF7shYPEL3(B) expressing cells had baseline levels of βGalactosidase staining when incubated in CSS for 6 days suggesting that the increase in
senescence as measured by β-Galactosidase staining in MCF7 cells upon estrogen
removal is dependent on YPEL3. The use of two separate shRNA constructs decreases
the likelihood that the effect observed by silencing YPEL3 is the result of an off target
effect, further confirming the specificity for the role of YPEL3 in estrogen removal
mediated senescence.
Since the increase in YPEL3 expression in MCF7 cells following estrogen
depletion was independent of p53 expression and dependent on ERα, I next investigated
the role of p53 and ERα in CSS induced senescence of MCF7 cells. Incubation of
MCF7shCON and MCF7shp53 cells (described in Figure 33) in CSS for 6 days led to an
increase in β-Galactosidase positive cells, both at approximately 45% compared to CM
incubated cells both with control β-Galactosidase positive percentages at 5% or below
(Figure 36A). This finding supports the previous finding that the increase in YPEL3
expression and senescence induction of MCF7 cells following estrogen depletion is
independent of p53.
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Figure 36: Removal of Estrogen Triggers ER Dependent and p53 Independent
Senescence in MCF7 Cells as Measured by β-Galactosidase Staining. (A) Top:
Histogram representing the average % β-Galactosidase positive cells per treatment
condition +/- standard error of the mean of at least 100 cells counted per treatment
condition in biological triplicate. Cells were incubated for 6 days in indicated
media. Bottom: Representative images of cells treated as in top histogram. Images
taken at 100X magnification and same exposure time. (B) Top: Histogram
representing the average % β-Galactosidase positive cells per treatment condition +/standard error of the mean of at least 100 cells counted per treatment condition in
biological triplicate. Cells were infected with shCON or shERa at an MOI of 5
incubated for 6 days in indicated media. Bottom: Representative images of cells
treated as in top histogram. Images taken at 100X magnification and same exposure
time.
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Further evaluation of MCF7 cells infected with either shCON or shERα at an
MOI of 5 followed by incubation in CSS for 6 days and β-Galactosidase staining
revealed interesting results. In correlation with the expression of YPEL3 demonstrated in
Figure 33, when ERα expression is reduced in MCF7 cells incubated in CM
approximately 20% of the cells scored β-Galactosidase positive (Figure 36B). This
increase in β-Galatosidase staining is not as high as the 40% of shCON infected cells
incubated in CSS which is most likely due to the incomplete knock-down of ERα in these
cells (see Figure34B) or that as stated previously, charcoal stripping serum removes more
than estrogen. Together this data supports that the induction of senescence of MCF7
cells deprived of estrogen is dependent on ERα but independent of p53.
Tamoxifen is widely used clinically as an estrogen receptor blocker and has been
demonstrated to reduce tumor burden in 50% of women with ER+ breast cancer
(Osborne, 1998). It has also been shown to induce a G0/G1 cell cycle arrest in ER+ breast
tumors, as mentioned previously. Therefore, I decided to evaluate Tamoxifen for its
ability to induce YPEL3 expression and cellular senescence of MCF7 cells grown in CM
(estrogen containing media). MCF7shLacZ cells treated with Tamoxifen compared to
VC showed an increase in β-Galactosidase positive cells (35% and 5%, respectively)
(Figure 37B) and YPEL3 mRNA (Figure 37A). While there was some induction of
YPEL3 mRNA in shYPEL3 expressing MCF7 cells treated with Tamoxifen, these levels
were insufficient to induce senescence. Only about 2% of the MCF7shYPEL3(A)
vehicle control treated cells scored β-Galactosidase positive while approximately 5% of
the MCF7shYPEL3(A) Tamoxifen treated cells scored β- Galactosidase positive (Figure
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Figure 37: Tamoxifen Induces YPEL3 Dependent Senescence in MCF7 Cells.
(A) RT-PCR analysis of YPEL3 and pS2 expression normalized to GAPDH in
MCF7shLacZ, MCF7shYPEL3(A) or MCF7shYPEL3(B) pooled, stable cell lines
incubated in CM containing 0.5 μM Tamoxifen or vehicle control (VC) for 6 days.
Error bars represent 95% confidence intervals. (B) Top: Histogram representing the
average % β-Galactosidase positive cells per treatment condition +/- standard error
of the mean of at least 100 cells counted per treatment condition in biological
triplicate. Cells were treated as in (A). Bottom: Representative images of cells
treated as in top histogram. Images taken at 100X magnification and same exposure
time.
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37B). These findings indicate that Tamoxifen can induce senescence in MCF7 cells and
that this senescence is dependent on YPEL3 expression.
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IV. Discussion
Uncovering the specific genes and regulatory mechanisms responsible for the
induction and maintenance of tumor cell senescence is an active area of research which
will hopefully lead to the development of new anti-cancer therapeutics, potential
biomarkers for diagnostic or prognostic purposes and many other advances in the
treatment of cancer. At the nexus of senescence induction is the p53 tumor suppressor
protein. This study was designed to investigate the activation of p53 and its subsequent
actions that lead to the induction of cellular senescence.
Reduction of HdmX Induces Cellular Senescence in Prostate Adenocarcinoma Cells
I first set out to investigate HdmX’s contribution to the senescence pathway. Like
MdmX in mouse embryonic fibroblasts, HdmX was demonstrated to block H-RasG12V
mediated senescence in human diploid fibroblasts (Figure 7). To assess the role of
HdmX interactions with p53 and Hdm2 on cellular senescence, point mutations were
made in HdmX inhibiting its ability to bind p53 or Hdm2 (HdmXG57A and
HdmXC437G, respectively). When substituted for wild-type HdmX in combination with
H-RasG12V, neither mutant was able to block H-RasG12V mediated senescence suggesting
that HdmX binding to p53 and Hdm2 are required to block oncogene induced senescence
(Figure 10).
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HdmX directly binding to p53 has been demonstrated to be required for its
negative regulation of p53, which most likely explains why HdmXG57A cannot block HRasG12V mediated senescence. Some of HdmX’s activities have also been suggested via
its direct interaction with Hdm2. For example, HdmX is shown to translocate to the
nucleus by binding Hdm2 (Migliorini et al., 2002) and the heterodimer of HdmX:Hdm2
has been shown to be more stable than either protein alone (Tanimura et al., 1999). The
nuclear cytoplasmic fractionation study in this thesis supported that HdmX binding to
Hdm2 facilitates its nuclear localization where HdmX must bind to p53 to inhibit
transactivation (Figure 11). The Western blots shown in Figures 8 and 11 also support
that HdmX:Hdm2 heterodimer is the more stable form of the protein because
HdmXC437G appeared less stable than wild-type HdmX or HdmXG57A when infected
at the same MOI. Defining these required binding partners for HdmX’s ability to block
H-RasG12V mediated senescence may provide further direction for the development of
effective small-molecules to trigger HdmX cytoplasmic localization.
Reports suggest that HdmX is over expressed in several tumors, most of which
maintain wild-type p53 (Table 1; Wade et al., 2009). Interestingly, 90% of pancreatic,
50% of colon and thyroid and 30% of all human tumors have mutated Ras (Saxena et al.,
2008) which makes the tumor phenotype of mutant Ras, wild-type p53 and high levels of
HdmX likely. Since HdmX can block H-RasG12V induced senescence in untransformed
human diploid fibroblasts as demonstrated in Figure 7, knocking down HdmX in tumor
cells with mutant Ras, wild-type p53 and high levels of HdmX was hypothesized to
induce senescence.
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In fact, using shRNAi targeting HdmX induced senescence as indicated by an
increase in beta-Galactosidase staining LNCaP cells (wild-type p53, mutant Ras, high
HdmX). To demonstrate that the increase of beta-Galactosidase positive LNCaP cells
upon sh-HdmX infection was specific to knocking down HdmX and not an off-target
effect of the short-hairpin construct, HdmX protein levels were rescued in LNCaP cell
using a Lentivirus-HdmX expression vector harboring a silent mutation that makes the
hdmX mRNA from this cDNA resistant to the hdmX short hairpin RNA with an
accompanied background level of senescence induction. These results support that the
specific reduction of HdmX in LNCaP cells leads to tumor cell senescence as measured
by beta-Galactosidase staining.
Huang and colleagues reported that epithelial tumor cells treated with Nutlin
became beta-Galactosidase positive; however, upon drug removal, these betaGalactosidase positive cells resumed proliferation (Huang et al., 2009). To confirm that
the beta-Galactosidase positive cells detected in our study upon reduction of HdmX
represented irreversible senescence, HdmX protein was added back after cells underwent
senescence (day 7) followed by an additional 7 day incubation and beta-Galactosidase
staining at day 14. In contrast to Nutlin treatment, reduction of HdmX protein in LNCaP
cells did not change the percentage of beta-Galactosidase positive cells, supportive of
irreversible senescence induction of these tumor cells.
As described, tumor cells have also been shown to undergo senescence following
treatment with chemotherapeutic drugs, radiation or differentiating agents in vitro and in
vivo (Roninson, 2003). The advantage of tumor cell senescence as an endpoint for anti97

cancer therapy has been supported by studies suggesting that senescent tumor cells are
cleared by the immune system allowing for subsequent tumor regression (Xue et al.,
2007; Ventura et al., 2007). These findings illustrate the potential clinical impact of the
senescence observed in LNCaP cells after reduction of HdmX.
HdmX as a target for anti-cancer drug design has been supported by a number of
studies. Treatment of tumors in mice that are over expressing MdmX with siMdmX has
been shown by Gilkes and colleagues to reduce tumor volume through an unknown
mechanism (Gilkes et al., 2006). Since the use of siRNA as a drug has had many clinical
trial failures (Tiemann et al., 2009), there is a current push to develop small-molecule
inhibitors that may have fewer off target effects. Once small molecule inhibitors of
HdmX are developed through an intense screening process, they must be examined for
their biological activity. While the findings discussed above outline a potential biological
assay to examine novel HdmX small molecule inhibitors, they also suggest that targeting
HdmX may lead to human tumor cell senescence.
The first small molecule inhibitor of MdmX, SJ-172550, was recently described
(Reed et al., 2010). This inhibitor is described for its ability to block the MdmX : p53
interaction by binding to the p53 binding pocket of MdmX (Figure 38). This inhibitor
was demonstrated to effectively kill MdmX overexpressing retinoblastoma cells.
Interestingly, SJ-172550 was also demonstrated to function in an additive manner when
combined with Mdm2 inhibitor, Nutlin-3a (Reed et al., 2010). Examining the
effectiveness of these small molecule inhibitors on senescence induction of LNCaP cells
along with other cell lines would provide further validation and mechanistic detail for
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Figure 38: The First Small Molecule Inhibitor of MdmX. (A and B) Space filling
model with overlaid Mdm2:Nutlin-3a (teal) with MdmX:SJ-172550 (pink) showing
SJ-172550 bound to the p53 binding pocket of Mdm2/MdmX. (C) Position of the
p53 peptide binding to MdmX based on the Mdm2/peptide crystal structure. Gray is
the surface of Mdm2, blue/green/red is the surface of MdmX. (D) Primary docking
pose of SJ-172550 to MdmX superimposed on the crystal structure of p53 peptide
bound to Mdm2. Gray is the surface of Mdm2, blue/green/red is the surface of
MdmX. (Reed et al., 2010).
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their future testing in an animal model. Also, development of additional MdmX small
molecule inhibitors targeting the MdmX : Mdm2 interaction may prove beneficial for use
in combination with SJ-172550 based on the data generated in this study using
HdmXC437G.
Expression of YPEL3 Induces Cellular Senescence
The re-activation of wild-type p53 by targeting HdmX in tumor cells, as described
above, led to the induction of cellular senescence. While p53 signaling is critical to
senescence induction, down-stream p53 targets required for the induction of cellular
senescence have not been fully elucidated. Uncovering these players of the senescence
pathway would represent potential drug targets useful in treating tumors containing
mutant p53, where re-activation of p53 itself is not an option.
A microarray screen where p53 was activated by silencing its negative regulators,
Hdm2 and HdmX, uncovered a potential p53 target, YPEL3 (Heminger et al., 2009).
The validation of YPEL3 as a direct p53 target was completed by biochemical assays
including ChIP analysis (Kelley et al., 2010); however, the biological role for human
YPEL3 was unknown. This study provides evidence that YPEL3 is growth suppressive
through the induction of cellular senescence in human tumor (MCF7 and U2OS) and
non-transformed (IMR90) cell lines. Expression of YPEL3 reduced colony formation in
MCF7 and U2OS human tumor cell lines and shYPEL3 expressing MCF7 cells
demonstrated increased cellular proliferation compared to shLacZ expressing control
cells supporting the growth suppressive activity of YPEL3. The induction of senescence
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by YPEL3 was confirmed via beta-Galactosidase staining along with senescence
associated heterochromatin formation (SAHF).
To begin to position YPEL3 within the senescence pathway, RNAi technology
was utilized in IMR90 cells (human diploid fibroblasts), a cell line often used in the study
of senescence due to its non-transformed nature and ability to undergo oncogenic Ras
mediated and replicative senescence. Knocking down YPEL3 blocked H-RasG12V
mediated senescence in IMR90 cells, suggesting that YPEL3 is a critical p53 target
during H-RasG12V mediated senescence. Two separate short hairpin lentiviruses targeting
YPEL3 were used in combination with H-RasG12V infection and both blocked senescence,
suggesting that the specific reduction of YPEL3 is sufficient to block H-RasG12V
mediated senescence. Furthermore, using RNAi targeting p53, it was demonstrated that
YPEL3 is most likely functioning downstream of p53 in the Ras mediated senescence
pathway.
Further probing of the senescence pathway using RNAi targeting p21 and p16
unveiled that YPEL3 is sufficient to induce senescence in human diploid fibroblasts and
that this senescence induction is independent of p21 or p16 expression. p16 and p21 are
known to play critical roles in non-transformed and tumor cell senescence (Shay et al.,
2004). However, senescence induction has also been observed in non-transformed and
tumor cell lines where p21 or p16 has been inactivated or is functionally absent,
suggesting that other genes may mediate cellular senescence in these backgrounds.
Therefore, YPEL3 may represent a novel cellular senescence mediator functioning
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independent from p16 and p21. Additionally, results in Figure 29A suggest that neither
p21 nor p16 are functioning downstream of YPEL3 during YPEL3 induced senescence.
Further evaluation of YPEL3’s ability to rescue H-RasG12V mediated senescence
blocked by reduction of p16 or p21 revealed intriguing results. While YPEL3 was able to
rescue H-RasG12V mediated senescence blocked by reduction of p16, it could not rescue
senescence in the presence of H-RasG12V and shp21. This finding will provide the
foundation for a future project aimed at uncovering why YPEL3 is not sufficient to
induce senescence in the presence of H-RasG12V and reduced p21. One possible
explanation is that in the presence of H-RasG12V and reduced p21, YPEL3 may induce an
apoptotic mechanism in IMR90 cells. This is supported by the observation that while HRasG12V, shp21 and YPEL3 triple infected cells are not scoring β-Galactosidase positive
they are also not proliferating like complete media or shLacZ infected control cells as
indicated by the reduced number of cells in the H-RasG12V, shp21 and YPEL3 infected
field compared to shLacZ infection control (Figure 39). Further investigation of this
observation is required to make any conclusions about YPEL3’s function in the presence
of H-RasG12V and absence of p21.
This study of YPEL3’s role in senescence has been limited to the H-RasG12V
mediated senescence model using human diploid fibroblasts. There are many ways to
induce tumor and non-transformed cells to senesce including, but not limited to, using
agents that induce oxidative stress or DNA damage (Shay et al., 2004). For example,
MCF7 breast carcinoma cells are shown to senesce in a p53-dependent manner after
treatment with the DNA damaging agent Doxorubicin (Adriamycin) (Elmore et al.,
2002). The modulation and dependence of YPEL3 gene expression can be evaluated
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Figure 39: YPEL3 May Induce Apoptosis in the Presence of H-RasG12V and
Absence of p21. Representative images of IMR90 cells infected as indicated at
the bottom of the image, which was taken at 100X magnification and same
exposure time. (Ras=H-RasG12V) Numbers listed for shLacZ, Ras and
Ras+shp21+YPEL3 indicate approximate total number of cells present in image.
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under this and other established cell culture conditions that induce senescence to further
investigate the role of YPEL3 in senescence induction. Generation of this data will
provide further mechanistic information describing how YPEL3 is involved in the
senescence pathway and may strengthen the argument to target YPEL3 as an anti-cancer
therapeutic.
YPEL3 is sufficient to induce accelerated senescence in human tumor and nontransformed cell lines, but it remains to be determined whether YPEL3 is involved in
replicative senescence. Using aged IMR90 cells, the relative expression of YPEL3 can
be monitored over passages to determine if YPEL3 mRNA increases as cells approach or
enter replicative senescence. RNAi targeting YPEL3 and LacZ (control) can also be
utilized to determine if knocking down YPEL3 is sufficient to block or delay replicative
senescence in IMR90 cells. These types of experiments can be used to determine if
YPEL3 has any role in replicative senescence, and if so, would further implicate YPEL3
as a tumor suppressor protein.
As previously mentioned, differences in the critical proteins involved in the
senescence pathway in mouse and human cell culture systems have been noted. Future
directions for this project include using a mouse model system, so I wanted to determine
if YPEL3 was also sufficient to induce senescence in MEFs to begin to investigate both
the mouse and human senescence pathways. Early data indicate that expression of
YPEL3 is sufficient to induce senescence in MEFs, also (Figure 40). As in IMR90s, it
will also be important to determine if YPEL3 has a role in replicative senescence in
MEFs. If loss of YPEL3 does enable MEFs to escape replicative senescence, then
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Figure 40: YPEL3 Is Sufficient to Induce Senescence in MEFs. MEFs
infected with CM, GFP, Ras (H-RasG12V) or YPEL3 were incubated under
selection for 7 days followed by β-Galactosidase staining. Histogram represents
the average % β-Galactosidase positive cells from 3 independent experiments +/SEM per treatment condition normalized to transduction efficiency determined by
% GFP positive cells. (CM = complete media, Ras = H-RasG12V). Representative
images from each treatment condition taken at 100X magnification and same
exposure time are shown below.
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cellular proliferation and transformation assays can be completed using MEFs to
determine if YPEL3 is in fact functioning as a tumor suppressor protein, which is yet to
be determined. More importantly, studies using MEFs may support knocking out YPEL3
in mice as a useful direction for the future study of YPEL3.
Further testing will be necessary to determine the mechanism through which
YPEL3 is functioning to induce cellular senescence. Uncovering YPEL3 binding
partners using either a yeast two-hybrid screening approach or co-immunoprecipitation
followed by mass spectrometry may reveal binding partners of YPEL3 and provide
direction for future mechanistic evaluation. Additionally, while a crystal structure of
YPEL3 protein is not currently available, structural modeling programs have been used to
determine a predicted structure from which correlations to function can be made
(personal communication, Kevin Kelley). Together, these types of studies may assist in
unveiling the detailed mechanism for YPEL3’s ability to induce cellular senescence.
YPEL3 Expression Increases Following Estrogen Depletion Leading to Senescence
If YPEL3 is in fact functioning as a tumor suppressor protein, then YPEL3
expression may be reduced in human tumor tissue compared to normal control. To
examine this hypothesis, eight different tumor types were screened for their mRNA
expression of YPEL3 revealing that colon, lung and ovarian tumors contained statistically
significant reductions of YPEL3 mRNA expression compared to normal controls (Kelley
et al., 2010; personal communication Rebecca Tuttle). While examining this data,
changes in YPEL3 expression were noted in breast tumor samples that appeared to
correlate with ER status (personal communication R. Tuttle, MD). In a gene expression
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profiling experiment where estrogen was added back to ER+ breast cancer cell lines,
YPEL3 was uncovered in a list of down-regulated genes all lacking a defined estrogen
response element (ERE) (Cicatiello et al., 2010). Therefore, we sought to examine
whether YPEL3 is regulated through estrogen receptor signaling.
To begin to investigate the role of the estrogen receptor in YPEL3 gene
regulation, MCF7 breast carcinoma cells (wild-type p53) were grown in charcoal stripped
serum (CSS) to remove steroid hormones including estrogen. These cells demonstrated a
4-fold increase in YPEL3 gene expression and corresponding increase in YPEL3 protein
compared to MCF7s grown in CM (Figure 30). No modulation of YPEL3 expression
was detected in an ER- breast tumor cell line (SKBr3) grown in CM compared to CSS
suggesting that the increase in YPEL3 upon estrogen removal occurs through the
presence of an estrogen receptor (Figure 31). The add-back of 1 nM β-estradiol reduced
YPEL3 mRNA compared to CSS alone while Tamoxifen blocked this reduction, further
supporting that the increase of YPEL3 expression upon CSS treatment was specific to
estrogen depletion and may be occurring through ER signaling.
YPEL3 was previously described as a direct p53-target gene (Kelley et al., 2010);
therefore, the next step was to determine if the increase of YPEL3 expression upon
estrogen depletion was dependent on p53. Using MCF7shp53 and MCF7shCON pooled,
stable cell lines, estrogen removal was demonstrated to increase YPEL3 expression
independent of p53. This finding was somewhat surprising and lead to the examination
of the YPEL3 promoter region for an estrogen response element (ERE). Transfac
(http://www.biobase-international.com/pages/index.php?id=transfac), a database
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designed to investigate transcription factor binding sites, predicted no classic ERE
contained within the YPEL3 promoter region, making the direct regulation of YPEL3 by
the estrogen receptor unlikely. It was important at this point to determine if the increase
of YPEL3 expression following estrogen removal was dependent on the presence of the
estrogen receptor or if there was some indirect mechanism through which estrogen
depletion was regulating YPEL3.
RNAi specifically targeting ERα in MCF7 cells was utilized to reveal that the
increase in YPEL3 expression after estrogen depletion is in fact dependent on the
presence of ERα. Together this data suggests that YPEL3 expression is inhibited by
estrogen in breast cancer cells at least indirectly through the estrogen receptor. While
examining the YPEL3 expression data was the first step, it was necessary to next
determine if the increase of YPEL3 expression following estrogen depletion as described
above translated to some biological activity. Since YPEL3 expression was demonstrated
to induce senescence in MCF7 cells (Kelley et al., 2010), senescence induction of MCF7
cells depleted of estrogen was first evaluated.
The increase in YPEL3 gene expression in MCF7 cells after estrogen removal
was accompanied by an increase in beta-Galactosidase positive cells, indicative of an
increase in senescence. A senescence-associated gene, PAI-1, was also up-regulated in
these beta-Galactosidase positive MCF7 cells, further supporting that these cells did in
fact undergo senescence. MCF7 cells are p16-null, therefore examining SAHFs in these
cells was not completed since SAHF formation has been shown to require functional p16
(Narita et al., 2006).
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Silencing YPEL3 lead to complete block of senescence induced by estrogen
removal in MCF7 cells suggesting that this senescence induction is YPEL3 dependent.
However, upon add back of β-estradiol to CSS, there was only a partial rescue of cellular
proliferation. Taken with the fact that when YPEL3 is silenced in MCF7 cells there in an
increase in cell growth compared to shLacZ expressing control cells, it is possible that
reduction of YPEL3 not only blocks senescence but allows for additional cellular
proliferation. This data suggests that YPEL3 may be functioning as a tumor suppressor.
Classic cellular transformation assays (as mentioned previously) will begin to address
this question.
The exact mechanism through which the estrogen receptor down regulates YPEL3
expression has not been determined. Based on the absence of an ERE within the YPEL3
promoter region a direct regulation of YPEL3 expression by the estrogen receptor is
unlikely. It has been observed that estrogen depletion of MCF7 cells led to an increase in
luciferase activity using a luciferase reporter construct containing a region of the YPEL3
promoter, suggesting that the increase in YPEL3 upon estrogen depletion is, at least in
part, due to increased transcription (personal communication Kevin Kelley). There are
many known transcription factor binding partners of the estrogen receptor that can be
investigated to determine through what indirect mechanism ERα is regulating YPEL3.
For example, there are probable GATA1 transcription factor binding sites within the
YPEL3 promoter which were uncovered using TFSEARCH (http://molsun1.cbrc.aist.go.
jp/research/db/TFSEARCH.html) and ENCODE (http://genome.ucsc.edu/ENCODE/).
The latter is a program designed to provide probable transcription factor binding sites as
determined by chromatin immunoprecipitation followed by high throughput sequencing.
109

Reports suggest that bound ERα binds to and negatively regulates GATA1, providing a
potential link from ERα to YPEL3 expression (Blobel et al., 1995).
Additionally, the increase in YPEL3 expression upon estrogen removal may be
explained by the RNA stability of YPEL3 under these conditions. The use of
cycloheximide to block translation can be used to begin to assess if RNA stability is the
mechanism of increased YPEL3 expression under estrogen deprived conditions. These
types of studies will provide the necessary information to begin to determine the exact
mechanism through which YPEL3 is regulated by the estrogen receptor and will provide
useful information for potential anti-cancer drug design.
The involvement of the estrogen receptor in MAPK signaling and Mdm2 function
has been studied using the H-RasG12V mediated senescence model (Suga et al., 2007). It
appears that ERα up regulates Mdm2 independent of p53, leading to suppression of p53
transcriptional activity (Phelps et al., 2003). This was further examined through use of
MEK inhibitors with anti-estrogen (IC1182,780) therapy. When cells were treated with
these two agents, the transcriptional activity of ERα was reduced followed by a reduction
of Mdm2 levels, which was accompanied by increased p21 and reduced cell growth
(Suga et al., 2007). The use of a MEK inhibitor, ER antagonist and PI3K inhibitor can be
examined for their ability to increase YPEL3 expression leading to senescence. This type
of data using a multidrug approach may provide support for designing anti-cancer
therapies targeting YPEL3 for patients with ER+, wild-type p53 breast tumors.
Conclusion
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This study was designed to identify critical upstream and downstream
components of the p53 signaling pathway leading to cellular senescence. Beginning
upstream, it was demonstrated that over expression of HdmX can block cellular
senescence, which may, at least in part, explain how HdmX is contributing to tumor
formation. Futhermore, reducing HdmX in a prostate adenocarcinoma cell line
containing wild-type p53, mutant Ras and high levels of HdmX led to tumor cell
senescence, suggesting that targeting HdmX in human tumors may be efficacious through
induction of tumor cell senescence. Next, YPEL3, as a direct p53 target gene, was shown
to function downstream of p53 and be required during H-RasG12V mediated senescence,
making YPEL3 an interesting protein to further investigate for its role in cellular
senescence.
The additional finding that expression of YPEL3 is increased in MCF7 cells
(ER+, wild-type p53) after estrogen removal, which correlated with the induction of
YPEL3-dependent, p53-independent senescence in these cells provided evidence that
YPEL3 may be a viable therapeutic target in ER+ breast tumors. Together these three
aims provide novel insights into the activation of p53 and one of its target genes that are
both involved in senescence induction.
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